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Developments and recent advancements in the
field of endogenous amino acid selective bond
forming reactions for bioconjugation
Oleksandr Konievab and Alain Wagner*a
Bioconjugation methodologies have proven to play a central enabling role in the recent development of
biotherapeutics and chemical biology approaches. Recent endeavours in these fields shed light on
unprecedented chemical challenges to attain bioselectivity, biocompatibility, and biostability required by
modern applications. In this review the current developments in various techniques of selective bond
forming reactions of proteins and peptides were highlighted. The utility of each endogenous amino
acid-selective conjugation methodology in the fields of biology and protein science has been surveyed
with emphasis on the most relevant among reported transformations; selectivity and practical use have
been discussed.
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Introduction
Bioconjugation is a set of techniques allowing site-specific
creation of a covalent link between a biomolecule and an
exogenous moiety that endow it with desirable properties. This
novel hybrid having the combined properties of its individual
components can serve, for instance, as a more stable and eﬃcient
therapeutic,1–4 an assembly for studying proteins in the biological
context,5–11 a new protein-based material,12–17 a microarray,18,19 a
biological material,20–24 a tool for immobilisation,25 and for
elucidation of the structure26,27 of proteins.
A large number of reactions exist to modify proteins.28 However,
site-specific conjugation continues to attract considerable research
eﬀorts to develop new methodologies that match continuously
increasing requirements of modern applications in terms of
selectivity, stability, mildness, and preserving biomolecule integrity.
For the purpose of this overview, the focus will remain on recent
developments in bond-forming approaches in bioconjugation of
native amino acid residues. Among about 20 diﬀerent amino acids
involved in protein composition, only a smaller number comprises
appropriate targets for practical bioconjugation methods. In fact,
only one-third of all amino acid residues represent chemical targets
for the vast majority of bond-forming approaches.
The bioconjugationmethodology of choice is selected according
to the intrinsic reactivity of the targeted amino acid residue
(acidity/basicity, electrophilicity/nucleophilicity, oxido-reductive
characteristics) and its specific special environment (in-chain,
N-terminal, C-terminal, location in a specific sequence, accessibility,
etc.). In this review we will thus present the known bioconjugation
strategies in regard to these parameters ranked in a descending
order of frequency they are reported in literature.
1. In-chain conjugation
1.1 Lysine
The use of chemical groups that react with primary amines is one
of the oldest andmost versatile techniques for protein conjugation.
Virtually all proteins contain primary amino groups in their
structure. They can be divided into two groups: the a-amino group
situated in the N-terminus of most polypeptide chains and e-amino
groups of lysine residue (Lys, K). Because these amino groups
possess pKa values of about 8 and 10 (for a- and e-amines
respectively), in a vast majority of cases they are protonated at
physiological pH and, therefore, occur predominantly on the
solvent-exposed outside surfaces of protein tertiary structures. As
a result, they become easily accessible to conjugation reagents
introduced into the aqueous media.
Deprotonated primary amines are the most nucleophilic
among the available functional groups present in a typical protein.
However, protonation drastically decreases their reactivity. As a
consequence, despite the generally higher intrinsic nucleophilicity
of Lys e-amino groups, they require higher pH values to be
uncovered by deprotonation, which allows distinguishing
a- and e-amino groups by adjusting the pH. That is to say, at
the higher pH level, when both types of primary amines are
deprotonated, Lys side chain amino groups are generally more
reactive towards electrophiles, while at the lower pH it is the
opposite because of their prior protonation (Fig. 1). At the
acidic pH all amines are protonated and possess no significant
nucleophilicity compared to other side chains present in proteins.
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In particular, free (non-disulfide-bonded) Cys residues are
much stronger nucleophiles and, if accessible, will readily be
modified by most amine-reactive reagents.
It is also to be mentioned that like any other parameters,
nucleophilicity and basicity, as well as solvent exposure and
accessibility of a particular amino group, are influenced by the
microenvironment and can vary substantially, regarding the
substrate. For instance, Westheimer and Schmidt have found
the actual pKa of the amino group situated in the active site of
acetoacetate decarboxylase to be 5.9, which is 4 pKa units less
than that of an ‘‘ordinary’’ e-amino group of lysine.29
Depending on reaction conditions, selective modification of
either N-termini (see Section 2) or Lys e-amino groups can be
achieved by using various chemical reagents. They generally belong
to one of the following classes (in the order of relevancy): activated
esters (fluorophenyl esters, NHS (N-hydroxysuccinimides),30
sulfo-NHS, acyl azides), isothiocyanates, isocyanates,31 aldehydes,
anhydrides, sulfonyl chlorides, carbonates, fluorobenzenes, epoxides
and imidoesters. Among this vast variety of reactive functions, NHS
esters (and theirmore soluble sulfo-NHS analogues) and imidoesters
represent the most popular amine-specific functional groups
that are incorporated into commercially available reagents for
protein conjugation and labelling.28
Despite their name, amine-reactive reagents are not always
entirely selective for amines. Firstly, as already mentioned
before, they will react with any other stronger nucleophile, if
the latter is present and accessible on a protein surface.
Particularly, it concerns cysteine, tyrosine, serine and threonine
side chains. Secondly, depletion of these highly activated
reagents by hydrolysis is inevitable in aqueous solution. The
rate of both side-reactions depends on the particular substrate,
the conjugation partner, pH, temperature, and buﬀer composi-
tion. Evidently, buﬀers that contain free amines, such as TRIS
(tris(hydroxymethyl)aminomethane), must be avoided when
using any amine-reactive probes, since the rate of the reaction
with buﬀer would greatly exceed that with protein amino groups.
1.1.1 Isocyanates and isothiocyanates. Amines undergo a
reaction with isocyanates to readily form stable ureas. However,
because of their susceptibility to deterioration during storage,32
isocyanates are much more diﬃcult to manipulate with and
thus are not as well commercially accessible as corresponding
isothiocyanates. They can though be easily prepared prior to
use from more stable acyl azides by Curtius rearrangement.
Using this approach, for instance, Palumbo and colleagues have
elaborated the synthesis of a heterobifunctional amine-thiol
crosslinker containing an isocyanate group on one end and a
thiol reactive maleimide group on the other end (Fig. 2).33
Several early studies were devoted to the elaboration of
isocyanate conjugation methodology,34,35 but proven to be especially
laborious and complicated mainly due to the high reactivity and low
stability of isocyanates. Therefore they are of deferred interest today,
being completely displaced by isothiocyanate-mediated approaches.
Both isothiocyanates and isocyanates can be obtained from the
corresponding aromatic amines upon reaction with thiophosgene
and phosgene respectively (Fig. 3).36
Isothiocyanate-based selective amino group modification
was first reported in 1937 by Todrick and Walker,37 who found
that the reaction of allyl isothiocyanate with cysteine in alkaline
medium results selectively in thiourea – the product of amine
addition to isothiocyanate. In 1950, exploiting the selectivity of
amino-terminal labelling of the peptide with phenylisothiocyanate,
Edman has developed a method for peptide sequencing that has
changed cardinally the protein science and is known today as
Edman degradation.38 Only 30 years later, Podhradsky´ et al. have
examined the reaction of isothiocyanates on complex substrates
and demonstrated that the addition of the thiol and phenolate
functions of cysteine and tyrosine residues is always prevalent, and
that only at pH 4 5 amino groups start to manifest themselves
in the reaction.39 While thiol and alcohol additions result in
reversible reactions to give dithiocarbamates and O-thiocarbamates
respectively, amines add themselves irreversibly, thus shifting the
reaction equilibrium towards thioureas (Fig. 4). One should however
keep in mind that, despite the reversibility of the addition of thiols
and alcohols to isocyanates, they can enhance the kinetics of their
hydrolysis to unreactive amines or ureas and therefore significantly
decrease the yield of the conjugation. Moderately reactive but quite
stable in water andmost solvents, isothiocyanates represent thus
an appropriate alternative to the unstable isocyanates. As a
consequence, they are much more popular in bioconjugation.
Ever since the introduction of fluorescent isothiocyanate
dyes as more stable analogues of corresponding isocyanates
for fluorescent labelling of antibodies by Riggs et al.40 in 1958,
Fig. 2 Synthesis of the p-maleimidophenyl isocyanate crosslinker via
Curtius rearrangement proposed by Palumbo and associates.33
Fig. 3 Synthesis of isothiocyanates and isocyanates from the corresponding
aromatic amines.36
Fig. 1 Deprotonation of diﬀerent types of amino groups present in protein
structure (more nucleophilic amine is encircled in red). Lysine e-amino
groups are more nucleophilic, but also more diﬃcult to deprotonate.
Generally, a pH of 8.5–9.5 is optimal for modifying lysine residues, while
near neutral pH favours selective modification of N-termini.
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they have found widespread use in research laboratories and
proved to be an eﬀective means for tagging proteins at specific
sites.41
Fluorescein isothiocyanate (FITC) is arguably one of the
most commonly used fluorescent derivatisation reagents for
proteins. For instance, it was reported by Tuls et al.42 that
cytochrome P-450 can be selectively labelled by FITC with 75%
yield of a single-labelled LYS-338 conjugate in TRIS (particularly
inappropriate buﬀer for amine-reactive reagents though) at
pH 8.0 and 0 1C. Burtnick43 has described selective labelling of
one out of 34 lysine residues of actin in borate buﬀer with 35-fold
excess of the reagent at pH 8.5. Such a high level of selectivity
towards the LYS-61 residue over other 33 lysine residues pre-
sent in proteins (Fig. 5, shown in red) remains unclear, but it is
hypothesised to be due to an anomalously low pKa value
thereof. Following reports of Miki and collaborators44,45 further
confirmed the selectivity of this labelling, yet without any
explanation of such specificity. Bellelli et al.46 were able to
covalently label ricin (pH 8.1, 6 1C for 4 h). In fact, the targets of
the isothiocyanate-mediated labelling of proteins elaborated
over the last 60 years are even diﬃcult to enumerate. It was
proven to be eﬀective in diverse applications such as tagging of
antibodies (usually in carbonate–bicarbonate buffer, pH 9),47–53
bleaching-based measurement of membrane protein diffusion
of FITC-labelled cells (pH 9.5, 24 1C),54 surface topography of
the Escherichia coli ribosomal subunit,55 a-actinin distribution
in living and fixed fibroblasts,56 characterisation of a proton
pump on lysosomes,57 and hematopoietic stem cells.58
The most stunning examples include 125I labelling by means
of isothiocyanates, elaborated by Shapiro and colleagues59 for
regional diﬀerentiation of the sperm surface (TRIS, pH 7.7,
12 1C for 30 min), and the application of a similar methodology
by Schirrmacher et al.60 for 18F radioactive labelling of RSA,
apotransferrin and bovine IgG (pH 9.0, room temperature for
10–20 min). Conjugation of antibodies with chelating agents
for further radiometal labelling of antibodies has been
described by several groups61–63 and is based on the use of
phenylisothiocyanate-containing probes. Brechbiel et al.64 went
even further by combining the chelating functionality with the
biotin fragment in a scaffold of trifunctional conjugation
reagents. The preparation of silica nanoparticles coated with
isothiocyanate groups and their use in apoptosis detection has
recently been elaborated.65
The classical protocol of isothiocyanate labelling involves
the use of 5–10 equivalents at a slightly basic pH in the range of
9.0–9.5.66,67 Resulting thioureas are reasonably stable in aqu-
eous medium and provide a suitable degree of conjugation.68
For example, Sandmaier and colleagues69 have recently demon-
strated that radiolabelling of the anticanine CD45 antibody
using isocyanate and isothiocyanate provides a more specific
delivery to the targeted CD45-expressing cells than a method
exploiting thiol–maleimide conjugation (see Section 1.3.2).
However, it has been shown by Banks and Paquette70 that,
compared to NHS ester based methodology, antibody conju-
gates prepared with isothiocyanates are less hydrolytically
stable and deteriorate over time. Moreover, the reaction of
NHS esters for amine labelling was found to be faster, to
give more stable conjugates for both model amino acids and
proteins, and to proceed readily at lower pH, compared
to isothiocyanates. Consequently, NHS esters are preferable
to isothiocyanates in many respects for synthesizing bio-
conjugates.
1.1.2 Activated esters. Because of the poor leaving ability of
the alkoxy groups, alkyl esters of carboxylic acids are inert to
amines in aqueous media.71 However, their substitution by
good leaving groups activates the carbonyl and renders it
susceptible to nucleophilic attack. It is worth remarking that
not only does such activation increase the reactivity of these
reagents towards free amino groups, but also often augment
their tendency to degrade in the presence of water.72 Although
many activating moieties have appeared over years, only a
limited number of them are of significant importance in
bioconjugation today. For instance, formerly of significant
importance, especially in the field of peptide synthesis, acti-
vated phenyl esters are almost of no use today in bioconjuga-
tion because of their lower kinetics and lower stability
compared to succimidyl esters.73–75 However, they continue to
reappear in certain studies.23
N-Hydroxysuccinimide (NHS) activated esters were intro-
duced in 1963 by Anderson et al. as a better alternative to
phenyl esters in forming the peptide bond.30,76,77 Possessing
high selectivity towards aliphatic amines, NHS esters are today
Fig. 4 Reaction of isothiocyanates with nucleophilic amino acid residues
present in proteins. Only the reaction of lysine and N-terminal residues
(considerable at pH4 5) results irreversibly in obtaining the thiourea. Although
the reactions of thiol and alcohol groups with isothiocyanates are reversible,
they can largely accelerate the rate of isothiocyanate hydrolysis.
Fig. 5 Selective fluorescent labelling of the Lys-61 residue (shown in
magenta) of rabbit skeletal muscle G-actin (pdb: 2VYP) reported by
Burtnick.43
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considered among the most powerful protein-modification
reagents. Although several studies drew attention to a certain
reactivity of NHS-activated esters with tyrosine,78–83 histidine,84
serine and threonine (especially when situated in certain locations,
see Section 1.2),85–90 these side reactions possess largely decreased
rates compared to the reaction with free amines and do not generally
hinder the amine-selective derivatisation. High concentrations of
nucleophilic thiols should however be avoided because, similarly to
isothiocyanates, they may increase the rate of probe degradation by
forming more easily hydrolysable intermediates (Fig. 6).
The optimum pH for NHS-mediated labelling in aqueous
systems was found to be lower than for other amine-selective
reagents and ranges from 7 to 8 units (compared with 9–9.5 for
isothiocyanates), which enlarges the prospect of its suitability
for modifying alkaline-sensitive proteins. Several elaborated
studies of the kinetics,72 the stoichiometry,91 and the selectivity
(in-chain versus N-terminal modification)92 of NHS-mediated
protein tagging have been recently reported.
Depending on the pH of the reaction solution and temperature,
NHS esters are hydrolysed by water (possessing a half-life of
4–5 hours at pH 7, 1 hour at pH 8 and 10 minutes at pH 8.6),84,93
but are stable to storage if kept well desiccated. Virtually any
molecule containing an acid functionality, or a moiety which can
give an acid, can be transformed into its N-hydroxysuccinimide
ester. While the activation with NHS generally decreases the water-
solubility of the carboxylate molecule, the utilisation of sulfo-NHS94
preserves or even increases the water-solubility of the modified
molecule by virtue of the charged sulfonate group. The develop-
ment of new reagents based on NHS chemistry can be sometimes
challenging,95 but the derivatives are frequently of very important
use.96–100 Many NHS derivatives for the preparation of affinity
reagents, fluorescent probes and cross-coupling reagents are now
commercially available, enabling wide access to investigations.
The formed conjugates are linked by means of a very stable
aliphatic amide bond with half-lives in the range of 7 years in
water.101 This excellent stability and biocompatibility of the
obtained bonds have provided an exceptional importance of
NHS esters in the field of bioconjugation.
NHS ester-mediated covalent conjugation for protein modifi-
cation has been first accomplished by Becker et al., who studied
biotin transport first in yeast74 and then applied this technique
to the covalent attachment of biotin to bacteriophage T4.102
Since then, the field of NHS-mediated conjugation of proteins
has been unceasingly expanding its employability in countless
applications.
Cross-linking of proteins often implies using NHS-containing
homobifunctional or heterobifunctional cross-linking reagents.
These were used for elucidation of protein–protein103–107 and
protein–drug interactions,108 protein structural and subunit
analysis,26,109 create protein complex models,110 and preparation
of protein conjugates with enzymes, drugs or other macro-
molecules.111–113
Homobifunctional NHS cross-linkers are generally used in
reaction procedures to randomly ‘‘fix’’ or polymerize peptides or
proteins through their amino groups. Adding such crosslinkers to a
cell lysate will result in the random conjugation of interacting
proteins, protein subunits, and any other polypeptides whose Lys
side chains happen to be in close proximity to each other. This
represents a methodology for capturing a ‘‘snapshot’’ of all protein
interactions at a certain instant of time. Using this approach, for
instance, Sinz and collaborators were able to elucidate binding
of calmodulin to mettilin, a polypeptide and principal compo-
nent of honeybee venom, without chromatographic separation
techniques.114 Cross-linking of the proteins with a number of
diﬀerent length NHS-homobifunctional cross-linkers, and the
following digestion of obtained products with trypsin and analysis
by HPLC enabled the possibility of three-dimensional structure
modelling of the calmodulin–melittin complex (Fig. 7).
Several applications however require the precision of cross-
linking which cannot be provided by homobifunctional cross-
linkers. For example, the preparation of an antibody–drug
conjugate (ADC) implies selective linking of a cytotoxic payload
to each molecule of the antibody without causing any antibody-
to-antibody linkages to form. For such application the combi-
nation of different selective approaches in one linker is needed.
Therefore, heterobifunctional crosslinkers are designed to
possess diﬀerent reactive groups at either end. These reagents
allow for sequential conjugations that diminish undesirable
self-conjugation and polymerisation. Sequential procedures
involve two-step processes, where heterobifunctional reagents
Fig. 7 Mode of binding of melittin in the calmodulin–melittin complex
(pdb: 2MLT and 1CDL) calculated from ambiguous distance restraints
derived from the cross-linking data by Sinz and associates.114
Fig. 6 Preparation of activated NHS-esters and their reaction with nucleo-
philic amino acid residues present in proteins. Similarly to isothiocyanates,
the reversible reactions of thiol and alcohol groups with NHS-esters largely
increase the rate of hydrolysis thereof.
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(often in excess to ensure high conversion levels) are reacted
with one protein using the most labile group of the crosslinker
first. After eliminating the excess of the nonreacted crosslinker,
the second protein is added to a solution containing modified
first protein and another reaction occurs with the second
reactive group of the crosslinker. According to the Pierce website
(Rockford, IL, USA), the most popular heterobifunctional cross-
linkers are those having amine-reactive NHS esters at one end
and thiol-reactive maleimides (see Section 1.3.2) at the other
end. Because of its less stability in aqueous solution compared to
maleimide, the NHS-ester group should usually be reacted first.
Takeda and co-workers115 used a bifunctional reagent that
contained a NHS function and a benzylthioester function to
prepare a DNA–protein hybrid. One of the fastest growing fields
requiring heterobifunctional crosslinkers today is targeted drug
delivery therapies – ADCs.22,116–120 They are constituted of three
main components: one monoclonal antibody (mAb), targeting
specific signs or markers of cancer cells, one cytotoxic agent, and
one linker molecule that allows covalent drug binding to the
mAb. The composition of trastuzumab emtansine (Kadcylas,
Genentech), an in clinic ADC for treatment of HER2-positive
metastatic breast cancer, is depicted in Fig. 8.
The first example of a ‘‘cleavable’’ NHS cross-linking
reagent, DSP, was reported by Lomant and Fairbanks93 and
allowed eﬀecting the reversal of the previously conjugated
fragments under mild conditions of disulfide bond reduction.
Further advances in the field have resulted in various types of
linkers, cleavable under mild nucleophilic conditions (EGS),121
at basic pH (BSOCOES),122 in the presence of periodate
(DST),123 or enzymatically.124 These found their applicability
for studies in basic and applied research. The reader is directed
to a recent review by Leriche et al.125 that provides an overview
of chemical functions that can be used as cleavable agents and
to a publication by Jin Lee126 for an overview of commercially
available cross-linking reagents.
Other combinations of functionalities have been studied
over the last 20 years and resulted in elaboration of hetero-
trifunctional127 linkers usually combining two bioselective
reactive groups and a functionality for anchoring the obtained
conjugate (e.g. the biotin moiety).
Many chemical probes widely used in bioconjugation contain
the NHS-fragment in their structure and are designed to react with
free amino groups of proteins. For example, biotinylation128–130 as
well as PEGylation2 of proteins are most commonly achieved using
NHS-activated probes today. It was recently reported by Anderson
and collaborators that biotinylation of antibodies with NHS-biotin
and their following adsorption on the surface of nanocrystal
quantum-dots (QD) results in obtaining highly efficient
QD-antibody conjugates for the detection of protein toxins.131
Other types of protein immobilisation on matrices have also
been reported.84,132,133 The Bolton–Hunter reagent (SHPP),134
allowing the conjugation of tyrosine-like residues for increasing
the yield of subsequent (radio)iodination, is also based on
N-hydroxysuccinimide chemistry.135–140 Elaborated in 1982 by
Ji et al.141 structurally similar SHPP photoactivable hetero-
bifunctional probes for cross-linking experiments have been
used in more than 100 studies ever since. The NHS ester-based
strategy for isobaric, stable isotope labelling of peptides142–144
has recently found more widespread application in proteomic
studies with simultaneous developments in enhancing peptide
detection by electrospray ionisation mass spectrometry.78,145
This list can be continued and arguably utilisation of NHS-
mediated techniques can be found in all major fields of protein
conjugation and represents a gold standard in bioconjugation.
1.1.3 Reductive amination of aldehydes. Aliphatic and aromatic
amines react under mild aqueous conditions with aldehyde groups
to form an imine (known as a Schiﬀ base). This intermediate can
then be selectively reduced by amild reducing agent, such as sodium
cyanoborohydride,146 to give a stable alkylamine bond. Although this
approach for aminemodification is not used in protein conjugations
as frequently as the activated ester or isothiocyanate method, it is to
be considered as preferable when themolecule to be attached has an
aldehyde group (or can be easily converted to an aldehyde) because
of its simplicity and mild reaction conditions.
Historically, the conjugation of oligosaccharides to proteins
has become the first target for this approach. In 1974, relying
on the exceptional ability of the cyanoborohydride anion
described three years earlier by Borch146 to reduce selectively
Schiﬀ bases generated in situ from an amine and an aldehyde,
Gray has illustrated the possibility of mild synthesis of carbo-
hydrate coated bovine serum albumin (BSA) and P150 protein
(Fig. 9).147 However, because of low kinetics of conjugation,
only 4 out of 59 BSA lysine residues (presumably those posses-
sing the lowest pKa values) were derivatised after 300 hours of
reaction.
Reductive amination of proteins proceeds most readily at
pH 6.5–8.5 where the reduction of aldehydes and ketones is
negligible, and, if feasible, in an alcoholic solution under
dehydrating conditions where the rate-limiting formation of
the imine is favoured. According to Allred and colleagues,148
the addition of sodium sulfate (500 mM)may largely improve the
coupling efficiency in aqueous media.
To date, reductive amination has played a central role in the
synthesis of carbohydrate–protein conjugates,20,149–151 which
have been used for years to study themolecular recognition of carbo-
hydrates.152 Among these conjugates, polysaccharide–protein
Fig. 8 Structure of an antibody drug conjugate (ADC) Kadcylas. SMCC
linker (shown in blue) serves for conjugation of the antibody and cytotoxic
payload (Mertansine, shown in red).
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conjugate vaccines such as Menactra, HIBTiter, and Prevnar are
FDA approved and used routinely for the prevention of invasive
bacterial infections (Fig. 10),20,153 and potential anti-infective
and anti-cancer agents are currently in clinical trials.23,151,154,155
The reader is directed to a recent comprehensive review of
Adamo et al.24 covering the current status and future perspectives
of carbohydrate–protein conjugates.
Another reported application of reductive amination includes the
preparation of an organic trialdehyde to be used as a template
for the synthesis of three-helix bundle proteins,156 protein
PEGylation157,158 and immobilisation.159
Reductive amination however possesses several drawbacks
preventing it from being generally applicable to protein con-
jugation.160 The most important is the necessity to use water-
sensitive sodium cyanoborohydride, which has the potential for
reducing disulfide bonds within proteins. As an alternative,
McFarland and Francis161 have reported a water-stable iridium
catalyst (Fig. 11). However, the eﬃciency of the method is lower
than that of the classical reduction with cyanoborohydride.
1.1.4 Sulfonyl halides and sulfonates. Introduced in 1952
by Weber162 for fluorescent labelling of macromolecules, dansyl
chloride (DNSC) was the first widely used sulfonyl chloride for the
modification of proteins. It has gained incontestable popularity
for the study of proteins after Hartley and Massey have success-
fully used it for the determination of the active centre of
chymotrypsin.163 DNSC-Edman degradation was proposed by
Gray164 to improve the ease and reproducibility of a classical
isothiocyanate-based Edman degradation.38
Sulfonyl halides are highly reactive but also very unstable,
especially in aqueous media at the pH required for reaction with
aliphatic amines. For example, Haugland and collaborators165
have demonstrated that the rate of hydrolysis of Texas Red (one
of the most widely used long-wavelength fluorescent probes)166
and Lissamine rhodamine B sulfonyl chloride was much higher
(complete hydrolysis within 5 minutes in pH 8.3 aqueous
solution) than that of corresponding NHS esters (both retained
most of their reactivity for more than an hour under the same
conditions). Yet, the formed sulfonamide bonds are extremely
stable and even survive amino acid hydrolysis,164,167 which
makes sulfonamide conjugates useful for the applications where
the stability of the conjugation bond is a crucial feature.
Optimal conditions of protein modification by sulfonyl
chlorides are those under which free amino groups most eﬀectively
compete with water for a limited amount of the reagent. It is
thus best done at low temperature at pH 8.5–9.5.168 At lower
pH values, the unreactive protonated form of amines slows the
labelling reaction compared to the hydrolysis by water, above
this range the reagent is hydrolysed too rapidly.169,170 In
practical experiments, a several-fold excess of the reagent is
usually added, providing the unused probe is hydrolysed to the
corresponding unreactive sulfonic acid after labelling. It must
be borne in mind that unlike other amine-selective reagents,
sulfonyl chlorides are unstable in dimethylsulfoxide, classically
used for the preparation of stock solutions, and should never
be used in this solvent (Fig. 12).171
Apart from being reported for fluorescent labelling of pro-
teins,172 sulfonyl chlorides were used to incorporate a chelate
moiety into proteins,173 to study hydrodynamic properties or
introduce long-lived fluorescence labels into macromolecules
Fig. 11 Modification of lysozyme (pdb: 2LYZ) using reductive alkylation
with a water-stable iridium catalyst developed by McFarland and Francis.161
Fig. 9 First example of reductive amination of lactose by bovine serum
albumin (BSA, pdb: 3V03; lysine residues are shown in magenta) described
by Gray.147
Fig. 10 Structure of Prevnar 13 vaccine. The bacterial capsule sugars, a
characteristic of the pathogens, are linked to CRM197, a nontoxic recom-
binant variant of diphtheria toxin (pdb: 4AE0), by reductive amination at
lysine residues and N-terminus (shown in magenta).
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using tagging with pyrene derivatives174,175 or as cross-linking
reagents.176
Because of their very high reactivity towards nucleophiles,
sulfonyl halides also form conjugates with tyrosine, cysteine,
serine, threonine, and imidazole residues of proteins;177 therefore,
they are less selective than either NHS esters or isothiocyanates.
These conjugates are however unstable and can be completely
hydrolysed under basic conditions.
Covalent immobilisation of proteins on hydroxyl group
containing carrying supports (such as agarose, cellulose, diol-silica,
or polylactic acid films) is often accomplished by transforming
the latter into corresponding sulfonates: tosylate, mesylate, or
tresylate,178,179 serving as good leaving groups (Fig. 13).180–182
Albumin, cytokines and other therapeutic proteins and peptides
were reported to undergo mild PEGylation by means of PEG
tresylates.183–185 Although rather specific to amino groups, the
chemistry of tresylate-mediated conjugation is not unique and
well defined. For instance, Gais et al. have shown that PEG–
tresylate conjugation can produce a product that contains a
degradable sulfamate linkage resulting in heterodispersity of
the reaction.186
1.1.5 Fluorobenzenes. Despite their utmost importance for
protein modification and amino group quantification since Sanger
and Tuppy’s work on the structure of insulin,187 derivatives of
fluoronitrobenzene are of limited usefulness for bioconjugation.
Compared to other aryl halides, fluoro-substituted nitrobenzenes
were found to be the most reactive in bimolecular nucleophilic
substitution reactions.188 They are usually regarded as amino-
selective reagents, despite their known reactivity towards thiolates,
phenolates and imidazoles, as the products obtained in these
reactions are either unstable at alkaline pH required for the reaction
(Tyr and His) or can be thiolysed by excess b-mercaptoethanol
(Cys).189
4-Fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F), which has been
introduced as a fluorogenic reagent for more than 30 years ago by
Imai and Watanabe,190 still remains important for several
applications, mainly pre-column derivatisation and enrichment
of peptides. The reader is referred to a recent review by Elbashir
et al.191 providing an excellent overview of the NBD-F applic-
ability to the analysis of peptides and to a complete overview of
NBD-mediated methodologies for the fluorescent labelling of
amino acid residues by Imai and associates.192,193
An elegant approach for improving protein crystallizability, still
remaining a major challenge in protein structure research,194
was elaborated by Sutton and collaborators195 and consists in
the introduction of a charged ammonium residue. It exploits
the amine-selective derivatisation of protein by 1-fluoro-2-nitro-
4-trimethylammoniobenzene iodide (Fig. 14) and results in
increasing the hydrophilicity thereof. Using their approach,
the authors were able to study the binding site196 and to obtain
crystalline derivatives of modified bovine insulin,197 which is
especially hard to crystallize without inducing structural changes.198
A similar protocol was used by Ladd et al.199 for chromophorical
PEGylation of proteins with polyethylene glycol fluoronitrobenzene
derivatives.
1.1.6 Imidoesters. First investigated by Hunter and Ludwig
in 1962,200 the reaction of imidoesters with peptides reached its
climax for protein modification ten years after, when Traut
et al.201 introduced the 2-iminothiolane reagent (today carrying
Traut’s name) for cross-linking. It allowed for producing
disulfide-linked dimers of neighbouring proteins on the intact
30s ribosome from E. coli using a two-step procedure: the
reaction of ribosomal amino groups with the imidoester function
followed by the mild oxidation of the obtained thiolate-charged
ribosomes (Fig. 15). An excellent review of the cross-linking
studies for the determination of ribosomal structure was pub-
lished by Nomura.202
Imidoesters react with primary amines to form amidine
bonds. A high specificity towards amines can be achieved when
alkaline conditions (pH 10) and amine-free media, such as
borate buﬀer, are used.202 This places imidoesters among the
most specific agents for amine labeling. Because the resulting
amidine bonds are protonated at physiological pH, positive
charges near modified sites are preserved during the conjugation
Fig. 14 Derivatisation of bovine insulin with 1-fluoro-2-nitro-4-trimethyl-
ammoniobenzene iodide described by Sutton et al.195 Only amine-containing
residues of A1 and B1 chains are shown. Two of the four tyrosine residues
present in chains A1 and B1 (not shown) also react with the probe under
described conditions.
Fig. 13 Schematic representation of the reaction protocol for immobilisation
of protein on PLLA film surfaces described by Ma et al.181
Fig. 12 Reaction of sulfonyl chlorides with amino groups present in proteins.
Hydrolysis of the starting material by water or dimethylsulfoxide171 (chloro-
dimethylsulfide, CDMS, is a leaving group) results in obtaining unreactive
sulfonic acid.
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with lysines and N-termini. Consequently, as was first demon-
strated by Wofsy et al.203 such modifications produce little or
no significant changes in the conformational properties and
biological activities of proteins.
Thiolates obtained after the ring opening of Traut’s reagent
by free amines enable a plentiful thiol-selective chemistry on
modified a- or e-amino groups of proteins (see Section 1.3).
Although, many imidoesters other than Traut’s reagent are
today commercially available (for example, see DMA, DMP, or
DTBP), the amount of described labelling imidoester probes is
rather scarce.
Schramm et al.204 have described the synthesis of fluorescent
imidoester dyes from corresponding nitriles; the approach was later
used by Bozler et al.205 for the preparation of dansyl containing
imidoester and selectivemodification of lysine residues in the active
site of glucose dehydrogenase. New readily available reagents for
the attachment of sugars to proteins via imidoester linkage,206
hydrophilic spin probes for determining membrane protein
interaction using EPR,207 immunoreactive probes,208 tyrosine-
like probes for radioactive labelling with 125I,209 protein PEGyla-
tion reagents,210 and the immobilisation of trypsin, yeast alcohol
dehydrogenase, and E. coli asparaginase onto several types of
organic polymer beads211 were achieved via imidoester conjuga-
tion and proven to have several advantages compared to other
existing methodologies, namely, deprivation of solubility issues
and retention of positive charge at the reaction site.
1.1.7 Miscellaneous amine-selective reagents. Several methods
of amine-selective modification of proteins were not included in
the main chapter, either because of scanty information available or
their applicability reduced to a specific substrate type and is not
general.
Azetidinone chemistry has recently been demonstrated by
Barbas and collaborators212,213 to have potential for selective
lysine labelling of a particular IgG framework, containing a very
reactive lysine residue with an unusually low pKa of about 6.
Some detailed procedures are described for a smooth opening
of a b-lactam moiety resulting in a b-alanine peptide bond.213
Discovered by Tietze et al. as two-step sequential procedures
for coupling of amines,214,215 squaric acid diester amine–amine
conjugation is now actively developed by Wurm et al., who have
recently reported their successful use for the one-pot preparation
of poly(glycerol)–protein216 and glycol–protein conjugates217 in
aqueous media (Fig. 16).
Dichlorotriazine derivatives were described for amine-selective
conjugation mainly as fluorescent dyes218,219 and PEGylation
probes.220–222 They were shown to possess high reactivity towards
protein amines. However, as was demonstrated by Abuchowski
et al.,220 because the hydrolysis of dichlorotriazine occurs readily
under slightly basic conditions (pH 9.2) needed for reaction to
take place with sufficient selectivity towards amines, a consider-
able excess of the probe must be used in the coupling reaction.
Banks and Paquette70 have conducted a comparative study of
three fluorescent probes, differing only in the moiety responsible
for the reactivity with amines: CFSE (NHS ester), DTAF (dichloro-
triazine) and FITC (isothiocyanate). It was found that the rate of
conjugation is significantly faster for the NHS ester compared to
the diclorotriazine probe, which, in turn, reacts faster than the
isothiocyanate derivative. Each conjugate provided a satisfactory
level of stability in solution over a period of 1 week at room
temperature, although the hydrolysis of the remaining, relatively
inert, chloro group of DTAF was observed (Fig. 17).
Arpicco et al.223 have prepared thioimidoester activated PEG-
containing derivatives and shown their superiority over the
NHS-activated analogue for gelonin modification (the reaction
was conducted in PBS at pH 7.4). In this particular case, PEGylation
with a less active, compared to NHS ester, thioimidoester derivative
resulted in the gelonin conjugate with higher inhibiting activity.
Ikeda and associates224 have recently described a protocol for the
preparation of the glutalaldehyde-functionalised PEG reagent,
allowing for protein PEGylation under mild reaction conditions.
Similarly, the modified protein exhibited higher biological activity
than when reacted with a corresponding NHS-activated PEGylation
reagent.
a-Halocarbonyls, such as iodoacetamides, can modify lysine
residues at pH 4 7.0,225 but the reaction rate is much slower
than the reaction with cysteine residues. Another class of
Fig. 16 One-pot, two-step squaric acid diester mediated glycosylation of
BSA (pdb: 3V03) described by Wurm et al.217 Up to 22 lysine residues of
the 59 present in BSA (30–35 are available for post-modification) could
be glycosylated with 25-fold excess of squaric diester and glucosamine
in 12 hours.
Fig. 17 Modification of BSA (pdb: 3V03) by the PEG-[14C]dichlorotriazine
probe reported by Abuchowski and colleagues (14C atoms are marked with
red stars).220
Fig. 15 Procedure of the cleavable crosslinking of the intact 30s ribo-
somes (pdb: 1J5E) described by Traut et al.201 Lysine residues (Lys-72 and
Lys-156) were chosen randomly for simplicity purposes (TEASH stands for
triethanolamine buﬀer adjusted to 3% 3-mercaptoethanol).
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reagents usually used in cysteine-selective conjugation – vinyl-
sulfones226 (see Section 1.3.3) – was recently reported to be
applicable for lysine labelling at slightly basic pH.227,228
Modification of Lys residues with acid anhydrides, including
succinic, citraconic, maleic, trimellitic, cis-aconitic, and various
phthalic anhydride derivatives belongs to a pool of classically
used protein modification methodologies229 and allows for
transforming nucleophilic amines into acids and, as a result,
enables carboxylate-selective chemistry thereof.
For more details of the practical aspects of using the above-
described methodologies, the reader is referred to a recent
review by Brun and Gauzy-Lazo230 on the preparation of anti-
body–drug conjugates by lysine conjugation.
1.2 Serine and threonine
With pKa values4 13, the hydroxyl groups of serine (Ser, S) and
threonine (Thr, T) are rather poor nucleophiles close to physio-
logical pH. No examples of direct conjugation of in-chain serine
and threonine have been therefore reported to date.
However, highly amine selective N-hydroxysuccinimide
(NHS) esters have been documented to give occasional side
reactions with hydroxyl side chains.83,90,92,231 In a series of
experiments, Miller et al. have demonstrated that the presence
of histidine in sequences of the type His-AA-Ser/Thr or His-AA-
AA0-Ser/Thr (where AA and AA0 stand for any amino acid) can
significantly increase the reactivity of hydroxyl groups toward
classical amine labelling agents (Fig. 18).85,86,88,232
Similarly,Ma¨dler and Zenobi have reported that the guanidinium
group of arginine can contribute to the reactivity of hydroxyl groups
toward NHS esters and catalyse the nucleophilic substitution.233 In
both cases, it is hypothesised that the imidazolyl and guanidine
moieties of histidine and arginine, respectively, catalyse the reaction
by stabilizing the transition state by means of hydrogen bonds and
electrostatic interactions. This promoting eﬀect is thought to be
responsible for side reactions on several substrates while using
cross-linking reagents.92,233
Despite the fact that methodologies of selective in-chain
serine and threonine labelling are rather scarce, these residues
are of special interest for bioconjugation when located on the
N-terminus (see Section 2.2).
1.3 Cysteine
Cysteine (Cys, C) is perhaps the most convenient target for
bioconjugation owing to the exceptionally high nucleophilicity
of its sulfhydryl (–SH) side chain which, and particularly in its
deprotonated thiolate form (–S), largely exceeds the reactivity of
any other nucleophilic function in proteins.234 Furthermore, its
relative rarity in proteins present in living organisms (1–2%)235,236
and the ease of its introduction into a specific site by site-directed
mutagenesis allows access to protein assemblies with a single
cysteine at a predetermined position.237 Even in proteins with
multiple cysteines, the multiplicity is usually much smaller com-
pared to lysines, which makes thiol-reactive labelling the preferred
approach over amine-reactive methodologies.
In proteins, thiols can also be generated by selectively
reducing cystine disulfides with reagents such as dithiothreitol
(DTT, D1532),238 2-mercaptoethanol (b-mercaptoethanol), or
tris[2-carboxyethyl]phosphine (TCEP).239,240 Generally, all these
reagents must be removed before conducting thiol-selective
conjugation, as they will compete with target thiols in proteins
otherwise.241 Unfortunately, removal of reducing agents is
sometimes accompanied by air oxidation of thiols back to disulfides.
Although, in contrast to the majority of thiol-reducing agents, TCEP
does not contain the thiolate group, there have been several reports
that it can react with a-halocarbonyls or maleimides and that
labelling is inhibited when TCEP is present in the reaction
medium.242,243
Direct labelling of the thiolate group is usually achieved by
either a nucleophilic addition or displacement reaction with
the thiolate anion as the nucleophile. The substantially less
dissociation energy of sulfhydryl groups compared to the
corresponding alcohols provides much higher acidity of the
former and, as a consequence, a wider availability of its slightly
nucleophilic anionic form at physiological pH.
1.3.1 a-Halocarbonyls. First reports on the use of a-halo-
carbonyl electrophiles, namely iodoacetamides, date back to
1935, when Goddard and Michaelis244 have first reported their
application in modifying and studying keratin. Even today,
almost 80 years later, these electrophiles are still among the
most widely used for the modification of cysteine, especially in
mass spectral analysis and peptide mapping of cysteine con-
taining proteins.245 Use of iodo compounds is typical because,
as iodide is a better leaving group among other halogens, these
render higher reaction rates for conjugation (the relative reac-
tivity is I 4 Br 4 Cl 4 F). Iodoacetyl-containing crosslinkers,
biotinylation reagents, immobilisation kits, and mass spectro-
metry tags are now commercially available (e.g. BIAM, SIAB,
UltraLinkt Iodoacetyl Resin and Gel, iodoTMTt). Although
corresponding maleimide reagents are more popular because
of their even higher reaction rates, the haloacetyl-mediated
conjugations are usually preferred for the applications where
the elevated stability and compact size of the generated linkage
(compared tomaleimide) are crucial. Indeed, such bioconjugates
Fig. 18 Nucleophilic attack of serine on the NHS-activated ester gives the
stable O-acylated derivative. In addition to His-AA-Ser, this stable inter-
mediate can be formed in the presence of linear sequences of His-AA-Thr
and His-AA-Tyr, where AA refers to any amino acid.
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degrade to S-alkyl cysteine derivatives only during amino acid
hydrolysis.
Typically, the reaction of sulfhydryl groups with haloacetamides
is conducted under physiological and alkaline conditions (pH 7.2–
9.0). When iodoacetamides are used, the reaction is preferably
carried out under subdued light in order to limit free iodine
generation, which has the potential to react with Tyr, His and
Trp residues. The reaction is most specific for sulfhydryl groups at
pH 8.3. The iodoacetyl group is known to react with other amino
acid side chains, especially when there is no cysteine present or if a
gross excess of iodoacetyl is used. For instance, free amino groups,
the thioester of methionine, and both imidazolyl side chain nitro-
gens will react with iodoacetyl groups above pH 7 and 5, although
with much slower kinetics.246 This, however, can be resolved by the
use of less reactive chloroacetamides247 or cautious control of pH
and incubation time.
It is to be noted that the local environment has a profound
eﬀect on the reactivity of cysteine residues in proteins. If
moderately reactive reagents such as iodoacetamide are used
for bioconjugation, this diﬀerence in reactivities makes it
possible to discern diﬀerent types of Cys moieties present in
the protein. Almost half a century ago, Gerwin248 reported
dramatic diﬀerences in the reactivities of chloroacetic acid
and chloroacetamide in the modification of the active-site
cysteine of streptococcal proteinase, which was found to be
due to the influence of the neighbouring histidine residue. As a
general trend, cysteine residues possessing lower pKa values are
more reactive when reaction is conducted under neutral or
slightly acidic conditions, owing to their greater degree of
dissociation and, as a consequence, higher concentration of
the corresponding thiolate anions in the medium. For instance,
Kim et al.249 have described a method for selective biotinylation
of low-pKa cysteine residues in proteins simply by conducting
the reaction at slightly acidic pH (Fig. 19).
Davis and Flitsch250 described a procedure for the selective
glycosylation of proteins at one or several sites by reacting the
carbohydrate-tethered iodoacetamides with cysteine side chains,
which allowed for preparing homogeneously glycosylated human
erythropoietin251 and dihydrofolate reductase.252
In 1948, Mackworth253 published his study on the reactivity
of the biochemical mechanism of the lachrymatory eﬀect of
certain war gases and first reported the reactivity of structurally
relevant a-bromoacetophenones for the inhibition of several
classes of thiol enzymes.
Despite advances made in the investigation of a-haloaceto-
phenones and related ketoximes for the modification of the
active sites of enzymes,256–259 their utility for the conjugation is
very limited because of various side reactions.
An interesting approach that allows photochemical conversion
of cysteine into corresponding thioaldehyde and then to aldehyde
thought to be formed by Norrish type II cleavage was reported by
Clark and Lowe.254,255 Photolysis of the enzyme, alkylated by a
bromoacetophenone derivative, results in spontaneous loss of
hydrogen sulfide from the generated thioaldehyde to give the
corresponding aldehyde (Fig. 20), which can either be utilised as
a locus for aldehyde-selective conjugation or be transformed into
the corresponding serine or glycine residue by reduction or transa-
mination respectively.
1.3.2 Maleimides. As early as 1949, maleic acid imides
(maleimides), products of the reaction of maleic anhydride and
amine derivatives, were introduced by Friedmann as cysteine-
specific reagents.260,261 Ever since, persistently gaining in popularity
maleimide-mediated methodologies represent today perhaps the
most often used functional groups for bioconjugation. This ismainly
due to their exceptionally fast kinetics and significantly high selec-
tivity toward the cysteine moiety in proteins.
The reason for such remarkable reactivity of maleimide
towards thiolates is worth being discussed. In general, the
electrophilicity of alkenes is defined by their ability to serve as
acceptors of nucleophile’s electron density, and thus interrelated
to the energy of electrophile’s p* orbital (its lowest unoccupied
molecular orbital, LUMO). Generally speaking, the rule is simple:
Fig. 19 Biotinylation of the low-pKa cysteine residue of rabbit muscle
creatine kinase (CK, pdb: 2CRK) by BIAM.249 The charge interaction
between the negatively charged thiolate and the positively charged amino
acid residues nearby results in a significantly lower pKa value of the CYS-
283 residue (6.5). Consequently, selective alkylation thereof becomes
possible in the presence of three other cysteine residues with higher pKa
values (8.0–9.0).
Fig. 20 Photolysis of the CYS-25 residue located in papain’s active site
(pdb: 1PPN) after its labelling with 2-bromo-20,40-dimethoxyacetophenone
results in the formation of the unstable thioaldehyde, which readily hydro-
lyses to give the corresponding aldehyde.254,255
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
09
/2
01
7 
12
:4
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
5506 | Chem. Soc. Rev., 2015, 44, 5495--5551 This journal is©The Royal Society of Chemistry 2015
the lower the energy of the alkene’s p* orbital – the faster its
reaction with nucleophiles. There exist two main approaches for
decreasing alkene’s LUMO energy: the direct attachment of an
electron-withdrawing group (EWG) and the straining of the
double bond. Although proceeding via two different mechanisms:
by decreasing the energy of both orbitals or by diminishing the
energetic gap between them, either approach results in lowering
the LUMO energy of the alkene and, as a result, in the increase of
its reactivity (Fig. 21). The unique reactivity of the maleimide
moiety owes to the fact that it exploits these two mechanisms
together.262,263
To date, a large variety of maleimide-based modifying
reagents are available from a number of leading biochemical
companies with even more being synthesised in laboratories
around the world for specific applications. The applications of
these reagents strongly overlap those of iodoacetamides,
although maleimides apparently do not react with methionine,
histidine or tyrosine.264,265
The optimum reaction conditions for maleimide-mediated
conjugation, namely conducting the reaction under near neutral
conditions (pH 6.5–7.5, Fig. 22), prevent the reaction of maleimide
with amines, because the latter requires a higher pH to occur. At
pH above 8 the hydrolysis of maleimide itself results in obtaining a
mixture of isomeric non-strainedmaleamic acids unreactive toward
sulfhydryls and can thus compete with thiol modification.28,266
Similarly, maleimide–thiol adducts hydrolyse, which either results
in complete deconjugation or causes a significant change in the
properties of the conjugate.266 Furthermore, especially at pH above
9, ring-opening by nucleophilic reaction with an adjacent amine
may yield crosslinked products.267
Schuber and co-workers269 have found that important
kinetic discrimination can be achieved between the maleimide
and bromoacetyl functions when the reaction with thiols is
conducted at pH 6.5 and 9.0, respectively.
Maleimide–NHS heterobifunctional reagents are especially
important for the formation of conjugates. Hydrolysis of both
the maleimide moiety and the generated thioester linkage is
considerably dependent on the type of chemical group adjacent
to the maleimide. Interestingly, the cyclohexane ring was found
to provide increased maleimide stability to hydrolysis due to its
steric effects and its lack of aromatic character. For this reason,
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC) and its water-soluble analogue (sulfo-SMCC) are today
among the most popular crosslinkers in bioconjugation. They are
often used in the synthesis of the protein–protein or protein–probe
assemblies such as antibody–enzyme or antibody–drug conjugates
respectively. These include enzyme immunoassays,270–274 carrier-
protein conjugates,275–277 albumin-binding prodrugs,278,279 and
even approved therapies.117,119,280,281
Short homobifunctional maleimides are commonly used to
explore and characterize protein structure (i.e., oligomerisation) or
protein interactions.282–288 Maleimide-mediated immobilisation of
biomolecules is often achieved either by direct conjugation13,289,290
or by prior biotinylation of the molecule of interest.291 The latter
approach has been used for protein enrichment,292 capture,293,294
and immobilisation on modified supports.295–298
Most of the optical thiol-selective fluorescent probes often
used as sensors formonitoring biological processes are represented
by maleimide-containing reagents.299–301 Another testament to
maleimide utility is its use in glycosylation,302 radiolabelling,303,304
studying protein interactions,305–308 and quantitation of cysteine
residues.309,310
Despite its successful application as a reagent for the chemical
modification of proteins, the irreversibility of maleimide’s addition
makes it impossible to regenerate the unmodified protein by con-
trolled disassembly of the conjugate. Such necessity is however often
desirable for in vitro or in vivo applications. Several studies were
devoted to a mild and specific hydrolysis of the imido group in
maleimide conjugates.312,313 These approaches turned the originally
irreversible maleimide-mediated thiol conjugation into the cleavable
methodology. However, the harsh reaction conditions of this
cleavage (strong basic conditions or the presence of a high
amount of imidazole) make them incompatible with many
fragile protein substrates.
Monobromomaleimide derivatives, introduced by Baker et al.314
in 2009, have expanded the class of reagents for the selective and
Fig. 21 Influence of an electron-withdrawing group (EWG) and cycle
strain on the frontier orbitals of alkenes, s-orbitals omitted (the form of
the orbital is presented approximately, based on the publication of Mercha´n
et al.268). Decreasing the energy of the LUMO (lowest unoccupied mole-
cular orbital) results in higher reactivity of the electrophile towards nucleo-
philes. Although via diﬀerent mechanisms, both the EWG and strain of the
cycle activate alkenes for the attack by nucleophiles.
Fig. 22 Conjugation of maleimide-functional poly(PEGMA) to the only
free CYS-34 residue of BSA (pdb: 3V03).311
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
09
/2
01
7 
12
:4
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 5495--5551 | 5507
reversible modification of cysteine (Fig. 23). In contrast to
methanethiosulfonates (see Section 1.3.6),315 monobromoma-
leimides allow much more stable conjugation of thiolates,
which are easily cleavable upon reaction with TCEP by the
addition–elimination sequence (Fig. 23).
Moreover, the initial modification of a protein resulted in
obtaining a thiol–maleimide moiety, which was shown to be
prone to a second thiol addition and resolved another recog-
nised drawback of maleimide-based methodologies, namely
the presence of only two points of attachment.316 Similar to a
non-substituted maleimide, the hydrolysis of thiol–maleimide
linkage results in a dramatic decrease in its reactivity towards
thiolates, which can be used for ‘‘switching off’’ the linker after
the first thiol addition (Fig. 24).317,318
1.3.3 Vinyl sulfones. The Michael-type addition of vinyl
sulfones (VS) is an attractive strategy for protein conjugation,
because of the elevated water stability of VS function and almost
quantitative yields of their reaction with thiolates.319–323 The reaction
of vinyl sulfones with lysine residues has been reported,320,322
however, occurring only at high pH values (pH4 9.3).
Initially, VS-mediated approaches have been used almost
exclusively for PEGylation of proteins with end-functionalised
PEG derivatives.322,324 Several studies on the immobilisation of
macromolecules on solid supports using vinyl sulfones were
reported, owing to the elaboration of new methods for the
preparation of VS-modified surfaces.319,320,325–327 Versatile VS-
containing probes, namely carbohydrates,227,328 chelating
agents,329 fluorescent tags,330,331 and biotinylation reagents331
were recently developed and applied in the bioconjugation of
proteins (Fig. 25). Ovaa and co-workers332 used vinyl sulfone
handle to conjugate enzymes to a ubiquitin-like protein. The
applications of VS-tags in proteomics have recently gained
popularity and have been reviewed by Lopez-Jaramillo et al.331
Vinyl sulfones react with thiols to form a stable thioether
linkage to the protein under slightly basic conditions (pH 7–8).228
The reaction may proceed faster if the pH is increased, but this
usually also increases the amount of side-products (namely the
modification of the Lys e-amino groups and the His imidazole
rings).320 The main advantage of VS-tags is their elevated stability
in aqueous solutions, compared to more reactive thiols and
maleimides, which can be subjected to ring opening or addition
of water across the double bond.185
1.3.4 Thiol–ene coupling. Discovered at the beginning of
the last century by Posner,333 free-radical-based hydrothiolation
of terminal alkenes, also called the thiol–ene coupling reaction
(TEC), has emerged as a powerful approach for the chemoselective
modification of both peptides and proteins.334,335 The initial step of
the reaction is light- and/or initiator-induced generation of the thiyl
radical. This adds to alkene in an anti-Markovnikov fashion to yield
the thioalkyl radical. This leads to the propagation of the radical
chain by abstraction of hydrogen from the other thiolate (Fig. 26).
The TEC conjugations (usually conducted in PBS-DMSO
buﬀer at pH 7.0–7.5) are compatible with oxygen and aqueous
media and are usually carried out upon irradiation at lmax
365 nm in the presence of Vazo44 (2,20-azobis[2-(2-imidazolin-
2-yl)propane]dihydrochloride) as an initiator. The resulting
thioether linkage is biologically stable and robust.
The first approach to protein conjugation namely glycosyla-
tion via TEC was reported by Davis et al. in 2009.336 However, it
consisted of photoinduced coupling of various glycosyl thiols
with site-specifically introduced unnatural L-homoallylglycine.
A complementary approach to peptide and protein glycoconju-
gation by photoinduced coupling on cysteines was first intro-
duced almost at the same time by Dondoni and co-workers.337
Fig. 24 ‘‘Switching oﬀ’’ the linker’s reactivity for second thiol addition
achieved by hydrolysis of the thiomaleimide linkage on the L111C mutant
of the SH2 domain of Grb2 (wild-type pdb: 1JYU).317
Fig. 25 Bifunctional labelling of horseradish peroxidase (HRP, pdb: 2ATJ)
with vinyl sulfone-functionalised tags described by Morales-Sanfrutos
et al.330
Fig. 26 Mechanism of photoinduced free-radical thiol–ene coupling
(TEC).
Fig. 23 Conjugate addition of the L111C mutant of the SH2 domain of
Grb2 (wild-type pdb: 1JYU) to bromomaleimide followed by second
addition of glutathione resulting in the generation of the vicinal bis-
cysteine adduct.316
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The 66 kDa globular bovine serum albumin (BSA) possessing
one free CYS-34 residue was selected as a model protein.
Surprisingly, it revealed that not only the one CYS-34 SH group,
as expected, but also two more SH groups arising from the
752 91 disulfide bond were modified. It was suggested that
such hyperglycosylation was due to well-documented disulfide
bond degradation by UV-irradiation,338 namely to an electron
transfer process from photoexcited tryptophan residues.
Furthermore, prolonged irradiation of the reaction mixture
up to 2 hours induced the introduction of seven glycoside
residues into BSA. Despite the necessity for UV-irradiation,
ensuing side-reactions, and often moderate yields,335 the fact
that, in contrast to the majority of thiol-selective methodologies,
TEC does not exploit elevated nucleophilicity of the thiolate but
its readiness for the generation of radicals makes it especially
tolerant to a wide range of functional groups. For instance,
Garber and Carlson339 have used this feature of TEC for selective
capping of thiols in the presence of thiophosphorylated groups,
free alcohols and amines.
Several approaches involving the combination of cysteine-
selective methodologies have been recently reported. Stolz and
Northrop340 studied the reactivity of N-allyl maleimides and
found this scaﬀold to be appropriate for consecutive two-step
conjugation of thiols: via (1) base-initiated Michael-addition to
maleimide moiety and (2) radical-mediated TEC of allyl-fragment.
Scanlan and associates341 developed the sequential NCL-TEC
approach (for more details on NCL, see Section 2.3.1) for the
functionalisation of the cysteine thiolate generated at the ligation
site during native chemical ligation.
1.3.5 Thiol–yne coupling. After the rise of TEC for biocon-
jugation, its sister reaction of the hydrothiolation of alkynes,
also referred to as thiol–yne coupling (TYC), began to receive
increased attention.342 Discovered in 1949 by Jones and colla-
borators,343 TYC allows introduction of two thiol fragments
across a carbon–carbon triple bond via a free-radical mechanism
similar to TEC. The first step of the anti-Markovnikov addition
of a thiyl radical to the triple bond yields an intermediate
vinyl thioether capable of undergoing a second addition of
the thiyl radical through the same mechanism, leading to the
1,2-dithioether (Fig. 27).
TYC occurs under the same reaction conditions as TEC and
smoothly proceeds at room temperature in aqueous solutions.
First trials on the applicability of TYC on peptides were
reported by Dondoni and collaborators in 2010.344 The authors
have demonstrated the possibility of dual glycosylation of a series
of peptides (up to 8 residues). Later on, Davis and Dondoni have
expanded the dual conjugation strategy for achieving sequential
glycosylation and fluorescent labelling of BSA (Fig. 28).345 Just
as with TEC, the reaction also occurs at cysteine residues of the
752 91 disulfide bridge.
The necessity of using a photo- or a chemical initiator in
both TEC and TYC conjugations represents the main drawback
of these methodologies, as the presence of free radicals results
in a series of side reactions, namely oxidation and crosslinking
of proteins.
1.3.6 Disulfide reaction. Simple air oxidation of two thiolates to
form a disulfide bond is probably the most straightforward among
cysteine-selective conjugation techniques. Very simplistically, it con-
sists of open to air stirring of a protein possessing a free cysteine
residue with a thiol-containing probe for several days under basic
conditions.346 Apparently, a large excess of the thiolate-probe is
required in order to reduce the likelihood of protein dimerisation.
Treatment with iodine347 was reported for the activation of cysteine
formation ofmixed disulfides. However, restricted control of product
distribution and long reaction times largely limits the applicability of
these methods for bioconjugation.
Diverse disulfides have been extensively used in the past
decade for the modification of cysteine by disulfide exchange.
This reversible reaction involves attack of cysteine thiolate at the
disulfide, breaking the S–S bond, and subsequent formation of a
new mixed disulfide. A well-known example of such reaction is
colorimetric quantitation of free sulfhydryls with Ellman’s
Reagent.348 Several symmetric disulfide-containing fluorescent
probes such as BODIPY L-cystine and fluorescein L-cystine are
commercially available. However, because there is no thermo-
dynamic preference for this disulfide exchange to pass one way
or another, labelling with non-activated disulfides generally
requires use of a large excess of the probe to achieve sufficient
levels of tagging.349 In contrast, related activated thiols, namely
thiosulfates (R–S–SO3
), thiosulfonates (R–S–SO2–R0, MTS), sul-
fenyl halides (R–S–X),350 pyridyl disulfides,351,352 and TNB-thiols
(derivatives of 5-thio-2-nitrobenzoic acid) contain good leaving
groups, which tautomerise to give unreactive forms thus shifting
the reaction equilibrium (Fig. 29).
PEGylation, fluorescent and biotinylation probes containing
thiosulfate (commercialised as TS-link reagents) and pyridylFig. 27 Mechanism of photoinduced free-radical thiol–yne coupling (TYC).
Fig. 28 Glycosylation and fluorescent labelling of bovine serum albumin
(BSA, pdb: 3V03) by TYC (first step) followed by TEC (second step) with
2,2-dimethoxy-2-phenylacetophenone (DMPA) as a photoinitiator.345
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disulfide motifs are today widely commercially available. Thio-
sulfonates were first introduced for bioconjugation by Davis
and co-workers353,354 in their work on the controlled glycosyla-
tion355 and further elaborated by Zhao et al.356 for site-selective
PEGylation of proteins. Recent advances resulted in the further
development of thiol activated methodologies towards selenenyl-
sulfides357,358 and even methanedithiosulfonates, allowing for
synthesizing trisulfide conjugates.359 Disulfide-based conjuga-
tion was recently reported for the preparation of antibody–
drug conjugates and studying the influence of the spacer length
on their stability.360 Diselene analogues of disulfide PEGylation
reagents were proposed by Jevsˇevar et al.361 as selective and
fast alternatives for coupling. Although high conversion yield
required the use of a large molar excess of the probe, this
elegant approach represents an interesting technology which
deserves further investigation.
The main factor that has gained popularity to methodologies
yielding disulfide and selenol-sulfide linkage is the reversibility
they aﬀord. However, the resulting conjugates are generally less
stable than those obtained using bromomaleimides315 (Section 1.3.2)
and can be readily cleaved with classical reducing agents such as
DTT, b-mercaptoethanol or TCEP. Yet, in the case of disulfides,
the modified protein can be made more stable and resistant to
reduction by the corresponding thioether-linked conjugate by
means of HMPT-mediated desulfurisation elaborated by Davis
and associates (Fig. 30).362 The use of hindered disulfides
represents another way to increase the resistance of generated
conjugates to cleavage.363
1.3.7 Disulfide rebridging. Use of thiol reactive reagents
often requires the necessity for recombinant introduction of a
free cysteine into the protein364 because most proteins do not
have a free cysteine.365,366 This new free unpaired cysteine may
cause disulfide scrambling, complicate protein refolding,364 or
lead to aggregation of the protein.367 In contrast, most of the
biologically relevant proteins possess at least one disulfide
bond in their structure.368 The direct reduction of disulfide
bonds followed by conjugation with thiol-selective reagents is,
however, usually inadmissible, since these are responsible for
their structure, stability, or function369,370 and must thus remain
bridged after the modification in order not to alter protein
tertiary structure.
In an attempt to resolve this problem, Brocchini et al.371
developed a clever methodology for the PEGylation of protein
disulfide bonds with a,b-unsaturated bis-thiol alkylating
reagents. Covalent rebridging of the two thiols derived from
the disulfide after its mild reduction allowed obtaining the
modified proteins with retained tertiary structure and biological
activity. Interferon a-2b (IFN) was used in the initial studies,
because it is representative of four-helical-bundle proteins with
accessible disulfide bonds. Following reduction of the disulfide
in IFN’s, the two free cysteines were re-joined using a three-
carbon linked functional PEG.368,371 The methodology was
further expanded to PEGylation of therapeutic proteins,368,372,373
antigen-binding fragments of immunoglobulin G,374 and poly
phosphocholine labelling of IFN.375 Simultaneously with the
introduction of previously mentioned monobromomaleimides,
Baker and co-workers have introduced a relevant class of
reagents containing a highly reactive dibromomaleimide or
dibromopyridazonedione scaﬀold, allowing rapid and eﬃcient
disulfide rebridging by installing a rigid two-carbon linker.316,376
This approach was first applied for equimolar PEGylation of
32-amino acid salmon calcitonin (sCT, Fig. 31)377 and very recently
for the preparation of homogeneous antibody conjugates.378,379
Although being very rapid (full conversion is achieved in less
than 5 minutes), dibromomaleimide-based conjugation resulted in
obtaining a small amount of the multimers while modifying
complex polypeptides.378 Developed by Baker et al.380 andHaddleton
et al.381 more stable and less reactive dithiophenolmaleimides
allowed avoiding this apparent drawback of dibromomaleimide
probes. In combination with benzeneselenols known for their
eﬃciency in the catalysis of disulfide cleavage, the dithio-
phenolmaleimide approach allowed selective antibody fragment
conjugation with no detectable formation of multimers and
conserving a high reaction rate (Fig. 32).378 Haddleton and
colleagues382 have recently reported an in situ one-pot preparation
of oxytocin–polymer conjugates using dithiophenolmaleimide-
containing probes.
Structurally similar to dibromomaleimides, but containing four
attachment points instead of three, dibromopyridazinediones (PD)
Fig. 30 Two-step protocol for the preparation of thioether linkage via
disulfide exchange reaction followed by HMPT-mediated desulfurisation
(P(NMe2)3, hexamethylphospotriamide) of the glycosylated mutant S156C
SBL (wild-type pdb: 1GCI).362
Fig. 31 One-pot reduction-PEGylation of the disulfide bridge of sCT
(pdb: 2GLH) followed by rebridging using dibromomaleimide.377
Fig. 29 (a) General scheme of protein labelling via the formation of a
disulfide bond. (b) Most relevant examples of activated thiols: thiosulfate,
thiosulfonate, 2-pyridyl disulfide, 4-pyridyl disulfide, TNB-like thiol.
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were recently described by Caddick et al.383,384 and provided a
platform for IgG antibody dual labelling.384 Namely, the authors
elaborated the preparation of a PD-linker containing two ortho-
gonal reactive handles in its structure: (1) a strained alkyne, which
readily reacts with azides in Cu-free strain-promoted azide–alkyne
cycloaddition (SPAAC), and (2) a terminal alkyne, which reacts with
azides in Cu-catalysed azide–alkyne cycloaddition (CuAAC). The
construct obtained after rebridging a reduced antibody with the
PD-linker was then used to selectively introduce two distinct
functionalities (Fig. 33).
An interesting disulfide stapling–unstapling strategy using
dichloro-s-tetrazine was developed by Smith and collaborators
(Fig. 34).385,386 In addition to their ability to be photochemically
cleaved (i.e., unstaple thus regenerating reduced disulphide
bonds; Fig. 34a), S,S-tetrazine macrocycles provide a possibility
for labeling by exploiting the reactivity of the tetrazine in the
inverse electron demand Diels–Alder reaction (Fig. 34b).
Organic arsenicals (similar to tetracysteine-selective biarsenical
dyes initially developed by Tsien and co-workers, see Section 4)
were recently exploited for eﬃcient protein–polymer conjugation
(Fig. 35).387 It is noteworthy that, in contrast to highly thiol-reactive
dibromomaleimides, these reagents demonstrated enhanced
selectivity for disulfide rebridging in the presence of free Cys
residues. Namely, while dibromomaleimides reacted near
quantitatively within 30 minutes with the free CYS-34 of native
BSA, organic arsenicals exhibited limited reactivity and demon-
strated only about 20% labeling over the same period of
time.387 The authors hypothesised entropy-driven affinity of
arsenicals for closely spaced dithiols to be the main reason of
such specificity.
1.3.8 Transforming to dehydroalanine. b-Elimination of
thiolate from the cysteine moiety turns this one of the strongest
nucleophilic side chain into a dehydroalanine moiety (Dha,
Fig. 36) representing an electrophilic centre for reactions with
nucleophiles. Such ‘‘umpolung’’ in terms of nucleophilicity–
electrophilicity opens an extremely interesting prospect for the
Fig. 33 Dual labelling of IgG antibody using dibromopyridazinediones
(PD, shown in orange).384 The construct obtained after rebridging of a
reduced IgG with a PD-probe containing a strained alkyne (reactive in
strain-promoted azide–alkyne cycloaddition, SPAAC) and a terminal
alkyne (reactive in Cu-catalysed azide–alkyne cycloaddition, CuAAC)
was subsequently labelled with two azide-containing probes (N3–R1 and
N3–R2).
Fig. 34 Protein stapling–unstapling using dichloro-s-tetrazine described
by Smith et al. (a) Rebridging of a disulfide bond of a 14-mer peptide using
dichloro-s-tetrazine and recovery of the starting product by photo-
cleavage of the resulting S,S-tetrazine macrocycle (irradiation at 312 nm)
followed by quenching of the thiocyanate intermediate with an excess of
cysteine. (b) Rebridging of thioredoxin (Trx, pdb: 2F51) after the disulfide
bond reduction followed by tagging of the resulting S,S-tetrazine with a
strained alkyne containing probe (BCN-fluorescein).
Fig. 35 Rebridging of reduced sCT (pdb: 2GLH) with an organic arsenical
((GSH)2-As(III)PPEGA480) followed by release of sCT upon addition of
ethanedithiol (EDT) described by Wilson et al.387
Fig. 32 Dithiophenolmaleimide approach for in situ disulfide bridging of
antibody fragments (pdb: 1QOK).378
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transformations, whose applicability is generally largely restricted
due to the general nucleophilic nature of amino acid side
chains. Namely, Pd and Rh catalysed reactions,388–391 Michael
addition,392,393 hydroboration.394
Site-selective incorporation of Dha into proteins may be
achieved by a considerable number of chemical transformations.
Historically, the first example of such reaction was reported by
Koshland and collaborators 50 years ago and consisted of transfor-
mation of nucleophilic serine of chymotrypsin to dehydroalanine via
selective sulfonylation followed by base-mediated elimination.396–398
The method, however, exploited the particularly high nucleophilicity
of the SER-195 residue located in the active site of chymotrypsin.
Logically, more general methods based on the exceptional nucleo-
philic properties of cysteine received increased attention in the years
to follow. These are represented in Fig. 36 and include: reduction–
elimination, representing an often observed undesired side-reaction
during reduction of disulfides; base-mediated elimination of acti-
vated thiolate, typically requiring temperatures incompatible with
protein substrates and thus not being of synthetic interest; oxidative
elimination, and bis-alkylation-elimination.395 Two last approaches
seems to us the most promising among available Cys - Dha
transformations and it is to these methodologies that we now turn.
1.3.8.1 Oxidative elimination. Oxidative elimination of thiolates
is readily achievable, but often required high temperatures and
severe reaction conditions yielded the methodology incompatible
with fragile protein substances.399 However, recent eﬀorts focused
on finding milder conditions to carry out these desulfurisations,
have resulted in developing two promising classes of chemical
reagents: o-mesitylenesulfonylhydroxylamine (MSH, Fig. 37),392,400
and bromomaleimides (above-mentioned for the generation of bis-
cysteine adducts).314
Basic conditions are generally required for the reaction to
achieve high conversion yields. Other amino acid residues may
also react with MSH and bromomaleimide, but the reaction
rates are largely inferior to those of thiolates and resulting
products are generally unstable in basic conditions and decom-
pose back to their starting unmodified forms.
1.3.8.2 Bis-alkylation–elimination. Conversion of cysteine to
dehydroalanine by means of bis-alkylation–elimination approach
was first introduced by Holmes and Lawton.401 Initially this
transformation implied quite strenuous reaction conditions and was
only compatible with a restricted number of protein substrates. Only
recently have Davis and collaborators395 reported a more general
method for Cys- Dha transformation by means of water-soluble
a,a0-dibromoadipyl(bis)amide (DBAA) allowing generation of Dha
moiety under mild conditions (37 1C, pH 7.0–8.0) at sufficiently high
yields. This approach was evaluated on several model proteins,
including SBL (see above),395 the single-domain antibody cAb-Lys3
A104C mutant,395 histone H3 (Fig. 38),393 AurA kinase domain,402
and GFP mutant.403
1.3.8.3 Other approaches. Despite recent advances in dehydro-
alanine-mediated conjugation methodologies, the inherent limita-
tions of these methods preclude their general use for peptide and
protein modification. None of these approaches enable general,
chemo- and site-selective incorporation of dehydroalanine into
proteins without the need for prior incorporation of an accessible
Cys residue. Several other approaches continue to appear and
are designed to overpass this problematic. These are oxidative
elimination of aryl-selenocysteine,399,404–408 utilising of lacticin
synthetase,409 transformation to selenocysteine thioethers.410
1.3.9 Miscellaneous thiol-selective reagents. An example of
a simple alkylation reaction that still remains relevant in
bioconjugation is aminoethylation. Known for more than half
a century,411,412 it allows transforming cysteine thiolates into
lysine mimicking thialysine residues by means of bromoethyl-
amines or aziridines. Obtained thialysines were validated as
appropriate synthetic substrates for further amine-selective
transformations (see Section 1.1). Furthermore, the method
was recently demonstrated appropriate for providing the access
to more peculiar methylated lysine analogues.413 The reaction
is typically conducted at pH 4 8.5 to ensure a high level of
cysteine deprotonation.
SNAr substitution chemistry approaches for cysteinemodification
in proteins were reported by several research groups.395,414,415 Davis
et al.395 utilised Mukaiyama’s reagent (2-chloro-1-methylpyridinium
iodide) to generate an arylated cysteine as an intermediate for
Fig. 36 Utilisation of Cys-Dha transformation for bioconjugation. (a) General
mechanism of the transformation. (b) Representative methods for the genera-
tion of dehydroalanine.395
Fig. 37 Conjugation of mutant S156C SBL (wild-type pdb: 1GCI) containing
a single, surface-exposed cysteine residue CYS-156 by oxidative elimination
followed by conjugation with thiol probes.392
Fig. 38 Dehydroalanine-mediated conjugation on histone 3 mutant H3.393
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conversion thereof to dehydroalanine. Pentelute and co-workers
have expanded the approach towards perfluoroaryls for protein
stapling and conjugation.414,415 Finally, Barbas and associates416
have developed a class of Julia–Kocienski-like methylsulfonyl-
functionalised reagents, that reacts rapidly and specifically with
thiols under biologically relevant pH (5.8–8.0). Notably, the
resulting conjugates possess superior hydrolytic stability com-
pared to cysteine–maleimide, which makes this methodology
appropriate for the preparation of stable protein conjugates and
PEGylated proteins (Fig. 39).
A strategy exploiting selective cyclization of peptides containing
three cysteines to generate combinatorial libraries of cysteine-rich
bicyclic peptides was recently developed. This approach is based on
utilisation of homotrifunctional linkers: TBMB (tribromomethyl-),
TATA (triacryloyl-), or TBAB (tribromoacetamide-containing
reagents).418,419
An eﬃcient gold-catalysed allene-mediated coupling reaction
has been recently developed by Che and colleagues.420 The
method allowed direct thiol-selective functionalisation of model
peptides and reduced RNase A (Fig. 40).
Reactions of thiols with electron deficient acetylenes have been
known for decades, being, however, mostly conducted in organic
solvents.421–425 Several examples of reactions in aqueous media have
been recently reported.417,420,426,427 Che and co-workers417 have
elaborated a versatile method for the selective cysteine labelling
of unprotected peptides and proteins in aqueous media with
arylalkynone reagents. Notably, modified peptides could be
converted back into the unmodified peptides by treatment with
thiols under mild reaction conditions (Fig. 41).
Interestingly, in contrast to arylalkynones, structurally similar
electron deficient acetylenes – 3-arylpropiolonitriles (APN) – were
recently reported as a prominent class of reagents for irreversible
tagging of cysteine.428,429 A superior stability of resulting con-
jugates in aqueous and biological media opens an interesting
prospect in many fields where stability of obtained conjugates is
crucial, e.g. for preparation of antibody conjugates possessing
increased plasma stability (Fig. 42).429
Oxanorbornadienedicarboxylates (OND reagents), strained
adducts of furans and electron-deficient alkynes, were found to
provide better water stability while retaining selective, rapid, and
fluorogenic reactivity towards cysteine compared to corresponding
alkynes.430 a,b-Unsaturated ketones and amides (typically acryl-
amides) can undergo Michael-addition.431,432 However, the rate of
addition is not generally high enough to provide it with competitive
advantages compared with other approaches. Internal Cys
residues were reported to accelerate native chemical ligation
(see Section 2.3.1), an especially selective approach for N-terminal
cysteine conjugation, via cyclic transition states.433–438
1.4 Tryptophan
Tryptophan (Trp, W) is the second (after cysteine) low abundance
amino acid with about 1% frequency (depending on the living
organism),235 but approximately 90% of proteins contain at least
one Trp residue in their sequence.439 The specific reactivity of
tryptophan in proteins is one of the most challenging problems in
bioconjugation. In spite of the variety of reagents introduced over
the years for selective modification of tryptophan, only a few can be
used for conjugation. For instance, such classically used species as
Koshland’s reagent (2-hydroxy-5-nitrobenzylbromide)440 or chloro-
sulfonium ions441 present a high degree of cross reactivity with
nucleophilic side chains, nonetheless still being used in numerous
studies. These are, for example, investigation of the role of trypto-
phan in active sites of enzymes,442 estimation of its content in
proteins,443 or determination of the surface accessibility of Trp
residues in proteins.444
1.4.1 Malondialdehydes. In 2007, further exploring the reac-
tivity of dicarbonyl compounds towards tryptophan described by
Teuber and colleagues445 40 years earlier, Foettinger et al.446 have
reported selective reaction of substituted malondialdehydes (MDAs)
Fig. 39 Labelling of the free cysteine residue of BSA (pdb: 3V03) with
Julia–Kocienski-like reagents.417
Fig. 40 Cysteine modification of RNase A (pdb: 7RSA) via gold-mediated
coupling with allenes.420
Fig. 41 Cleavable labelling of BSA (pdb: 3V03) with arylalkynone reagents
elaborated by Che and associates.417
Fig. 42 Preparation of IgG (pdb: 1IGY, red sticks represent four interchain
disulfide bonds) conjugates with increased plasma stability using 3-aryl-
propiolonitriles (APN) described by Wagner and collaborators.429
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
09
/2
01
7 
12
:4
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 5495--5551 | 5513
with the indole nitrogen of the Trp side chain of 8-mer peptide
PTHIKWGD under acidic conditions (Fig. 43). The obtained
substituted acrolein moiety with a remaining reactive aldehyde
group can be further converted to a hydrazone using hydrazide
compounds, or using other methodologies for aldehyde con-
jugations. Hydrazine, phenylhydrazine and secondary amines
such as pyrrolidine were reported to act as cleavage reagents
and allow releasing the free tryptophane after conjugation.
To overpass selectivity issues, namely a known side reaction
with Arg side chains,448 the conditions for the reactions with
MDA, the hydrazone formation and the cleavage of the MDA
derivative, had to be optimised concerning pH, buﬀer, temperature,
and reagent. No side reactions of MDAs were observed only under
strongly acidic conditions, such as aqueous TFA (80%). The
following hydrazone formation requires approximately 50–100 fold
molar reagent excess at a pH of 5–7 and sometimes increasing the
temperature to 50 1C. Although unstable at acidic conditions and
when the reagent excess is removed, the hydrazone bond remains
firm in alkaline medium (pH 4 9). The optimal conditions for
the cleavage were found using hydrazine (applied as the dihydro-
chloride salt) in ammonium acetate solution at a pH B 3.
Demonstrably, these rather rough reaction conditions prevent
this methodology from finding widespread use for sensitive
protein targets, yet allowing its application in proteomics on
peptide digests.449
1.4.2 Metallocarbenoids. The same drawback is shared by
another approach involving vinyl metallocarbenoids described in
2004 by Francis and collaborators.450 The authors have shown, that
two Trp residues of horse heart myoglobin can be selectively tagged
by a stabilised vinyl diazo compound in the presence of Rh2(OAc)4
(Fig. 44). Diﬃculties reminiscent to the known instability of the
rhodium carbenoid intermediate in aqueous media451 were over-
come by using an unusual additive – hydroxylamine hydrochloride –
that was found to facilitate the reaction and enhance efficiency of
the tryptophan modification pathway relative to hydrolysis of
metallocarbene. However, the use of an excess of the corresponding
diazo compound is usually required (at least 4 equivalents) and a
2 :3 mixtures of N-alkylated versus 2-alkylated products (Fig. 44) are
generally obtained in moderate yields.450,451
The initially reported reaction conditions tolerated several
aqueous solvent systems and proceeded at room temperature.
Yet, acidic conditions (pH 1.5–3.5) were still necessary for
efficient protein labelling and stood out as the main drawback
preventing this approach from being generally applicable. For
instance, in the same work, authors have stated that myoglobin
was denatured and the heme dissociated from the protein due
to the high acidity of the medium.
To address these limitations, following eﬀorts of the same group
were to improve the pH range of the tryptophan modification
methodology.452 For hydroxylamine was found to be ineﬀective at
generating rhodium carbenoids at pH Z 6, a wide screening of
commonly used buﬀers, as well as additives structurally similar to
hydroxylamine H2NOH, was conducted in order to identify appro-
priate conditions. From these studies, tBuNHOH was found to be
highly eﬀective at promoting carbenoid addition. Despite the
precise mode of action for tBuNHOH remains unclear, the authors
attributed the substantial increase in catalytic activity to a specific
interaction between this additive and Rh2(OAc)4. They speculated
that, in contrast to hydroxylamine, tBuNHOH binds to Rh2(OAc)4
through the oxygen, rather than the nitrogen, the latter being
disfavoured by the bulky tert-butyl substituent (Fig. 45a), and
increases both the stability and the reactivity of the complex at
neutral and slightly basic pH.
Interestingly, in the same work, the authors have demon-
strated the key role of solvent accessibility of residues in
determining the outcome of conjugation on tyrosine using
rhodium metallocarbenes. Human FK506 binding protein
(FKBP) was identified as a suitable substrate for the study.
The only Trp residue (TRP-59) of a wild type FDBP (containing
an additional C-terminal threonine residue) is located at the
base of the binding pocket, and therefore is unavailable for
modification under nondenaturing conditions (Fig. 45b).
To overcome these diﬃculties, a labelling strategy based on
tryptophan mutagenesis followed by chemoselective modification
with rhodium carbenoids was utilised. Tryptophan-containing
FKBP proteins were expressed in E. coli with C-terminal
intein fusions containing a chitin binding domain for aﬃnity
Fig. 43 Selective labelling of Trp side-chain in a 8-mer peptide PTHIKWGD
with malondialdehyde described by Foettinger et al.446 The peptide struc-
ture was simulated using RaptorX web server.447
Fig. 44 Modification of horse heart myoglobin (pdb: 1YMB) with rhodium
carbenoids described by Francis et al.450 A 100 mM solution of myoglobin
was exposed to stabilised vinyl diazo precursor (10 mM) and Rh2(OAc)4
(100 mM) for 7 h. N- and C-derivatisation of indole rings of both Trp
residues – TRP-14 and TRP-7 – were identified by the mass reconstruc-
tion. An excess of hydroxylamine hydrochloride (75 mM) is crucial for the
efficiency of the conjugation, although its mode of action was not
elucidated.
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purification and short tryptophan-containing peptides (Fig. 45c).
Indeed, these newly obtained mutants with solvent accessible
Trp residues showed significant level of conjugation (more than
40%) under optimised non-denaturating conditions at room
temperature.
In 2010, further developing the rhodium-carbenoidsmethodology
for selective tryptophan labelling described 6 years before by Francis
et al.,453 Popp and Ball have reported structure-selectivemodification
of aromatic side chains (expanding its scope to include Tyr and
Phe residues) using proximity-driven approach (see Section 5 for
details).454 Structurally similar to Rh2(OAc)4, metallopeptide
complexes with a dirhodium center bounded with two glutamate
residues were envisioned to provide delivering of the catalyst to a
close proximity of the reactive side chains by exploiting the coiled
coil matched peptides,455 for molecular peptide–peptide recogni-
tion (Fig. 46).
By combining residue-selective chemistry with secondary-
structure recognition, the authors have provided a strategy for
selective covalent modification of biomolecules. However, only
simple diazo reagents without functional handles were used in
controlled environments on model peptide substrates.
In the following year, the same group has extended their
initial studies to examine the reactivity of whole proteins in a
complex, cell-like environment.456 For this, the proximity-driven
catalysis approach was applied to a recombinant maltose binding
protein (MBP), fused with the 21-amino-acid tryptophan-containing
coil (almost identical to one used in the initial publication, Fig. 46).
Directly after the expression, the lysate was subjected to
metallopeptide-catalysed biotinylation. A single band in Western
blot analysis indicated highly selectivemodification of themodified
MBP protein with no nonselective modification to be observed.
1.5 Histidine
Histidine (His, H) is the only amino acid with a pKa in the
physiological range, hence often found in active sites of many
enzymes and is of crucial importance in mechanisms where
abstraction or donation of a proton is needed. Because of its
pKa value, both the acid and base forms are present at physiological
pH (Fig. 47). Most of the studies on catalytic activity of enzymes and
protein–protein interactions involving histidine-containing active
centres were done by measuring the influence of site-specific
modifications of His residues on the activity of the macromolecule.
Main factors influencing histidine reactivity are (1) the pKa of the
individual His residue, (2) solvent exposure of the residue, and (3)
hydrogen bonding of the imidazolium ring. A vast number of
studies have been conducted to date, nonetheless, exploiting a
small number of chemical functions.
1.5.1 Epoxides. In 2004, Li et al. described two epoxide-
containing fluorescent probes459,460 for selective labelling of
histidine. A high selectivity of probes towards free histidine in
the presence of a 1000-fold excess of other nucleophilic amino
acids459 and in human serum460 (Fig. 48) was achieved after 2
to 3 hours of incubation at 80 1C in NaOH solution (pH 11–12).
Fig. 45 Optimised metallocarbenoids-based approach, described by Francis
and collaborators.452 (a) Proposed binding of tBuNHOH with Rh2(OAc)4 at
pH 6.0. O-Coordination is favoured due to a lower sterical hindrance of
tert-butyl groups with acetate ligands. (b) Crystal structure of wild type FKBP
(pdb: 1A7X), containing a single, buried tryptophan residue TRP-59 (shown
in magenta), which is unavailable for modification under nondenaturating
conditions. (c) A peptide tag (IQKQGQGQWG) incorporated into fusion
FKBP protein expressed in E. coli as C-terminal intein fusion. The total level
of modification was estimated to be in excess of 40%.
Fig. 46 Selective covalent labelling of the TRP-9 residue of the peptide
QEISALEKWISALEQEISALEK with its complementary dirhodium metallo-
peptide KISALQKQKESALEQKISALKQ described by Popp and Ball.454 The
rhodium cluster, chelated with two glutamate residues, is brought closer
to the reactive Trp residue by peptides coil self-assembling, resulting in
selective peptide modification on TRP-9. Peptide structures were simulated
using the RaptorX web server.447
Fig. 47 Tautomerisation equilibrium of the neutral imidazole side chain
(base forms A and C) occurring through the acid form B.457 Form A is
somewhat favoured over C at neutral and acidic pH, while at basic pH the
form C is preferred.458
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The authors suggest that these probes can be used for
specific labelling of His residues in proteins if a mild reaction
condition (lower reaction temperature but longer reaction time)
was used, but no example of such application was given. Moreover,
considering known reactivity of epoxides with primary amines,
thiolates, and hydroxyl groups, such selectivity towards histidine at
physiological pH seems improbable.461
An aﬃnity-based labelling approach (see Section 4) based on
the epoxide opening was developed by Hamachi and collaborators
for selective histidine labelling of bovine carbonic anhydrase
II.462,463 Labelling reagents investigated by the authorsmust consist
of at least three major fragments: (1) a benzenesulfonamide ligand
directing specifically to bCA, (2) a reactive electrophilic epoxide for
protein labelling, and (3) an exchangeable hydrazone bond between
the ligand and the epoxide group for removing the ligand by
hydrazone/oxime-exchange and restoring the enzymatic activity
(Fig. 49a). Further developing their approach,463 the authors added
an iodophenyl or acetylene handle on the epoxide-containing
fragment to enable the possibility of further derivatisation of
the obtained conjugate by Suzuki coupling464 or Huisgen
cycloaddition465 either after or before removing the ligand from
the active site of the enzyme (Fig. 49b).
1.5.2 Complexes with transition metals. The aﬃnity of
transition metal ions to histidine in aqueous solutions was
known for decades.466 Copper and nickel ions have the greatest
aﬃnity for histidine and this property is the most often used for
protein purification by immobilised-metal aﬃnity chromato-
graphy (IMAC), exploiting the synergetic coordination eﬀect of
oligo-histidine tags (see Section 4). Meanwhile, recently
reported by Wang et al., histidine-specific iridium(III)–probe
for peptide labelling demonstrates an excellent example of
selectivity based on exceptional coordination properties of only
one or two His residues (Fig. 50).467 Further exploring the
advantage of the previously described iridium(III)-complex,
used by Wong and colleagues for luminescent labelling of
histidine-rich proteins,468 authors showed its applicability for
histidine labelling in cell-imaging studies.
Although, reckoning obtaining of the coordination com-
plexes to conjugation techniques would be stretching a point,
they are however included in this survey because of histidine
liability to complexation and increased stability of obtained
complexes to decomposition.
1.5.3 Michael addition. Several examples of histidine-
selective Michael addition to the carbon double bond of con-
jugated aldehydes – 2-alkenals – were found during studies of
oxidative modification of proteins.469,470 Even though alkenals
are known for the modification of the other basic amino acid
residues in the protein,471 Zamora et al. succeeded in achieving a
high level of histidine ligation in bovine albumin by incubation
Fig. 48 Fluorescent probes, described by Li et al. for selective ligation of
histidine.459,460
Fig. 49 Aﬃnity labelling, hydrazone–oxime-exchange reaction, and
Suzuki coupling reaction on the surface of bCA (pdb: 1V9E) described by
Hamachi and collaborators.463 (a) Principal structural fragments of the
probe: a benzenesulfonamide ligand responsible for targeting bCA; an
electrophilic epoxide responsible for reactivity towards vicinal His residues
HIS-2 and HIS-3 (shown in magenta), cleavable hydrazone bond, respon-
sible for the recovering of the enzymatic activity; an iodoaryl moiety,
utilised for the further bioorthogonal transformation via Suzuki coupling.
(b) Dual labelling of bCA in situ: fluorescent labelling of the HIS-2 or HIS-3
alkylated intermediate by Suzuki coupling with a coumarine derivative,
followed by biotinylation by hydrazone/oxime-exchange.
Fig. 50 Luminescent histidine selective peptide tagging.467 (a) Labelling
of a N-terminal histidine-containing HTat peptide (HRKKRRQRRR).
(b) Labelling of a dihistidine motif placed in the middle of a P450dHTat
peptide (MLAKGLPPKSVLVKGGHHGRKKRRQRRR).
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in PBS buffer (pH 7.4) at 37 1C (Fig. 51), however, a reaction of
Lys residues was also observed.470 Using similar conditions – the
incubation in phosphate buffer (pH 7.2) at 37 1C – Uchida and
Stadtman469 were able to tag selectively insulin (which contains
no sulfhydryl groups) with 4-hydroxynon-2-enal. In both studies, the
authors suggest only His residues are modified, but definitive
evidence on this point is absent. Obtained conjugates contain active
aldehyde residues and represent examples of protein carbonylation,
allowing their derivatisation with aldehyde-selective reagents.472
1.5.4 Miscellaneous histidine-selective reagents. Some
examples of the selective histidine tagging by reagents that,
in general, react more avidly with other nucleophilic residues
were reported to date. For instance, Pramanik and colleagues
achieved dominant PEGylation rh-interferon-a2A on histidine
at mildly acidic levels of pH with a classic amine PEGylation
succinimidyl carbonyl precursor.473 Another group reported
selective reaction of His residues of D-amino acid oxidase with
dansyl chloride in 0.05 M phosphate buﬀer at pH 6.6.474 These
reaction conditions resulted in virtually complete inactivation of
the enzyme after the reaction and its complete reactivation after the
reaction with 0.5 M hydroxylamine (NH2OH). Such reactivation
excludes reaction of primary amino groups, and amino acid
analysis suggested that the reaction had not occurred with an
oxygen nucleophile such as serine or tyrosine. Even a-halo carbonyl
compounds – phenacyl bromides, a-halo carboxylic acids and
amides – classically known for their selectivity towards thiols
electrophiles as were found to be histidine selective on several
substrates and in carefully tuned conditions.475–479
Described by Pauly in the beginning of the 20th century,480,481 the
reaction with diazonium salts has been only used for colorimetric
determining of His residues482 and was not further elaborated for
bioconjugation. Other classical examples of chemical modification
of histidine are mainly reactions with pyrocarbonate, sulfonyl chlor-
ides, sulfonic esters, phenacyl- and acylbromides and activated
esters.229 These electrophiles react readily with other nucleophilic
groups presented in proteins (thiols, amines, alcohols, or guanidino
groups) and require a careful tuning of the reaction conditions to
achieve suﬃcient selectivity. For instance, at low pH (generally o
6.0) these reactions are quite selective for histidine, as the main side
reaction with the e-amino group of lysine proceeds very slowly.483
Reader should, nonetheless, be aware, that these examples
do not represent a general rule, but an exception from it. To
avoid the reactions of more nucleophilic functions, the His
residuemust have been located in a uniquemicroenvironment476,477
or have an enhanced nucleophilic character,478 but even in this
case, prior modifications of highly reactive Cys residues are often
inevitable.479
1.6 Tyrosine
Tyrosine (Tyr, Y) is one of the important amino acid residues which
is known to be the active centre in many enzymes (notably tyrosine-
specific protein kinases) and is used in signal transduction and cell
signalling.484,485 Occurring with intermediate to low frequency in
native proteins, tyrosine is often considered as an attractive target in
bioconjugation, despite being often partially or completely buried
due to the amphiphilic nature of the phenolic group.
The reactivity of tyrosyl moiety is easily influenced by its
deprotonation, which is a function of the microenvironment
inside the protein. All described methodologies take advantage
of either the peculiar chemical properties of the electron-rich
aromatic ring, or the easiness of the tyrosine hydroxyl group to
be transformed into highly reactive phenolate.
1.6.1 O-Derivatisation. Although O-acetylation of the tyro-
syl residue with acetic anhydride and N-acetylimidazole is
arguably the most widely used technique for tyrosine modifica-
tion,229 its application for conjugation is rather limited. Mainly,
these limitations are due to low selectivity of acylation in the
presence of other nucleophilic amino acid residues and modest
stability of obtained conjugates.
An elegant approach – the affinity labelling – allows surpassing
the selectivity issues of tyrosine acylation by ligand-tethered directing
of the reaction. In the case of tyrosine-selective modification, an acyl
transfer catalyst is connected to a ligand with a high affinity to the
target protein.462,486 The acyl group activated by the anchored
catalyst is brought to the binging pocket of the protein and transfers
an acyl moiety on the nucleophilic Tyr residue in close proximity.
Utilizing this methodology, Hamachi et al.486 demonstrated selective
tagging of Y51 residue of Congerin II (Fig. 52) using a suitable
saccharide as a ligand to the target lectin (carbohydrate-binding
protein) and DMAP (4-dimethylaminopyridine) as an acyl-
transfer catalyst. In a similar way, Broo and collaborators487
have demonstrated the possibility of a site-specific acylation of a
Fig. 51 Michael addition of His residues of bovine albumin (pdb: 3V03) to
4,5-epoxy-2-alkenal described by Zamora et al.470
Fig. 52 Sugar-DMAP (4-dimethylaminopyridine) assisted Y51-specific
acylation of Congerin II described by Hamachi et al.486 Schematic repre-
sentation is made using lactose-ligated Congerin II crystal structure
published by Muramoto et al.488 (pdb: 1IS4).
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tyrosine residue situated in an active site of human glutathione
transferase (hGST).
Miller and collaborators have shown that biotinylation with
NHS esters (see Section 1.1.2) may result in preferential O-acylation
of hydroxyl-containing residues – serine, threonine and tyrosine
(though to a greater extent of the first two) – when they are located
two positions next to histidine (i.e. in sequences His-AA-Tyr, where
AA refers to any amino acid).85,88
Several approaches for labelling involve the initial modification
of tyrosine and successive conjugation of an obtained intermediate.
For instance, an ortho-nitration of tyrosine with tetranitromethane
(TNM)489 or peroxynitrite490 results in obtaining of o-nitrotyrosine
that can be then reduced by sodium dithionite (Na2S2O4) to form
an o-aminotyrosine.
Although much less reactive than aliphatic amines at neutral
pH, the aromatic amine of o-aminotyrosine can selectively
react with amine-reactive reagents at lower pH.491,492 Namely,
Nikov et al.492 have demonstrated that selective labelling of
aminotyrosines is achievable in the presence N-terminal and
e-amino groups of lysines by using NHS-activated ester at
particular reaction conditions (acetate buﬀer, pH 5.0, 2 hours).
Exploitation of the pKa diﬀerence between aminotyrosyl residues
and other reactive groups in proteins (4.75 for aminotyrosine,
whilst much higher values for N-terminal and side-chain amino
groups, see Section 1.1) allows selective labelling thereof. The
method was validated on model peptides and then applied to a
human serum albumin modification (Fig. 53).
Despite the reaction of TNM and peroxynitrite with proteins
being reasonably specific for tyrosine, side reactions with
histidine, methionine and tryptophan have been reported, as
has oxidation of sulfhydryl groups. The latter would seem to be
the most common side reaction, as it can result in disulfide
bond formation and the formation of oxidation products such
as sulfone and sulfenic acid derivatives. As a general rule, it is
normally assumed that the reaction of nitration reagents with
Cys residues proceeds equally well at pH 6 and pH 8, while the
reaction with tyrosine occurs at pH 8 and not at pH 6.
In a like manner, the phenol group in Tyr residues can be
initially ortho-formylated with chloroform in an alkaline medium
to a salicylaldehyde derivative, and then undergo a reaction
with ortho-phenylenediamine derivatives to form fluorescent
benzimidazoles as conjugation products (Fig. 54).493,494
Further exploiting themethodology developed by Trost and Toste
for selective O- and C-alkylation of phenols with p-allylpalladium
complexes,495,496 Francis et al., have demonstrated the possibility
of selective allylic alkylation of surface-exposed tyrosines of several
full-size proteins.497
1.6.2 O-Oxidative coupling. In 1995, Kodadek and co-workers498
reported that Ni(II) complexed with a Gly–Gly–His (GGH) was
chemically activated by oxone (KHSO5) or magnesium mono-
peroxyphthalate (MMPP). A Ni(III) oxo intermediate is hypothe-
sised to promote protein cross-linking.499 Other peptides,
notably His6
500,501 or the entire ribonuclease A protein,502
which can be incorporated into proteins of interest at the
genetic level, have been shown to be effective ligands for nickel
catalysed oxidative cross coupling.
The photoactivable metal-catalysed version of tyrosine oxidation
chemistry is significantly faster than the one achieved by Ni(II)–
peptide complexes. It has been largely exploited by Kodadek and
co-workers for cross-linking of closely associated proteins.503–505
These coupling reactions are hypothesised to occur through
the addition of tyrosyl radicals to adjacent Tyr residues
(Fig. 55). It is worth mentioning, that in some cases nearby
Fig. 53 Two-step biotinylation of HSA (pdb: 1AO6) described by Nikov
et al.492 Preferential nitration of TYR-138 (shown in magenta) and TYR-411
residues of HSA with peroxynitrite was achieved using protocol described
by Jiao and colleagues.490 Aminotyrosine of the peptide 138YIYEIARK144,
obtained after the step of reduction with sodium dithionite and following
digestion of nitrated HSA with trypsin, were selectively modified with a
cleavable biotin-containing reactant at pH 5.0.
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tryptophan and other nucleophilic side chains can also participate
in oxidation.503 For more details, the reader is directed to a review
by Bonnafous and a publication of Francis that provide an excellent
overview of oxidative cross-linking techniques.507,508
The use of cerium(IV) ammonium nitrate (CAN) – a classical
one-electron oxidant – for chemoselective ligation on tyrosine
was demonstrated by Francis et al. (Fig. 56).509 After the
optimisation of reaction conditions, the authors could achieve
modification of tyrosine-containing proteins with high yields at
neutral pH and low substrate concentration and applied this
strategy to modify both native and introduced residues on
proteins with polyethylene glycol (PEG) and small peptides,
although dealing with the concurrent reaction of Trp residues.509
Notwithstanding the issue of specificity, photo-oxidation
and oxidation of techniques of tyrosine ligation continue to
be of considerable interest for the study of protein–protein
interactions,510 mapping multi-protein complexes,511 or assembling
of macromolecules.512
1.6.3 Diazonium reagents. Diazonium reaction of tyrosine
has been of special interest ever since its introduction by Pauly
in 1915.481 In 1959, inspired by these pioneering eﬀorts, Higgins
and Harrington advanced the use of this methodology and tried
applied it to complex proteins.513 The authors concluded that the
reaction was not confined to the tyrosine and emphasised its
competitive nature and strong dependence on the relative concen-
tration of protein and diazonium salt. Moreover, strongly acidic
conditions generally required for the preparation of diazonium salts
from anilines,514 are not compatible with pH-sensitive proteins.
Together with a relative instability of diazonium salts and the
prerequisite of their preparation just prior to use, these drawbacks
prevented this methodology from the widespread use.
The optimised conditions have nonetheless allowed its
application for selective modification of tyrosines on the surface
of bacteriophage MS2,515,516 the modification of the tobacco
mosaic virus,517 and the direct conjugation on proteins.518 Francis
and co-workers have demonstrated that highly reactive diazonium
salts (i.e. containing electron withdrawing groups in their struc-
ture) should be utilised in order to achieve eﬃcient Tyr targeting
and avoid concurrent reaction with Lys and His residues (see
Section 1.5.4).517 Recently described by Barbas et al., formylbenzene
diazonium hexafluorophosphate reagent519 represents an elegant
example of a stable ready-to-use reagent for tyrosine labelling and
introduction of an aldehyde bioorthogonal tag, capable for future
bioorthogonal modifications (Fig. 57).
1.6.4 Mannich-type reaction. Albeit with no control of selec-
tivity, tyrosine conjugation via Mannich-type cross-linking reac-
tion have been first reported by Fraenkel-Conrat and Olcott520
and proceeded through the conjugation of tyrosines with imines
formed in situ by condensation of lysine amino groups and
formaldehyde. The reaction conditions, namely the necessity of
using high concentrations of formaldehyde and significant
heating, limit the utility of this approach for the vast majority
of biological applications.
Fig. 54 Two-step tyrosine modification by selective formylation of the
tyrosyl residue at the ortho position of its phenolic moiety (reaction with
chloroform in potassium hydroxide solution) and further derivatisation of
the resulting aldehyde described by Kai et al. and Ishida et al.493,494
Fig. 55 Transition metal catalysed oxidative cross-linking. (a) Schematic
representation of the protein–protein cross-linking, described by Burlin-
game et al.506 The tyrosyl radical generated from ecotin (pdb: 1ECZ)
D137H mutant after the abstraction of an electron with Ni(II)–GGH
complex reacts with additional tyrosine residue on nearby protein that
are in close proximity due to a significant protein–protein interaction to
give a dimer. (b) Chemically activated by MMPP or oxone as stoichiometric
oxidants, Ni(II)–peptide complexes can be used as efficient catalysts of
cross-linking. (c) Photochemically activated by visible light in the presence
of (NH4)2S2O8 or Co(III)(NH3)5Cl2
+ as electron acceptors, transition metal
complexes are used as catalysts of cross-linking.
Fig. 56 PEGylation of four solvent-accessible Tyr residues of chymotry-
psinogen (pdb: 1EX3) reported by Francis et al.509 (only Y171 residue
is shown for simplicity reasons). Intermediate tyrosyl radical, generated
in the presence of cerium(IV) ammonium nitrate (CAN), gives two addition
products with electron-rich aniline derivative (O- is preferred over
C-arylation).
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The three-component Mannich-type methodology – involving the
in situ reaction between a Tyr residue, an amine and formaldehyde –
was reincarnated more than 50 years later by Francis et al.521 The
authors demonstrated the possibility of selective modification of
tyrosine residues of a-chymotrypsinogen A under mild condi-
tions (pH 6.5, 25–37 1C) and at low concentration of the protein
(20–200 mM). However, 18 hours of incubation were needed to
reach a reasonable level of tagging (66% in the case of a
fluorescent labelling, Fig. 58). The same group then used this
to incorporate synthetic peptides into full-sized proteins.522
Despite recognised selectivity issues of a three-component
Mannich-type approach for tyrosine labelling,523 its main
advantage is the possibility to easily vary the participating
partners: an aldehyde (Fig. 58, shown in blue) and an aniline
residues (Fig. 58, shown in violet). In the following publication
on the subject, Francis et al. have demonstrated the viability of
NMR-based characterisation of the conjugate isotopically
enriched by incorporation of 13C-formaldehyde into the coupling
reaction.523 Interestingly, while a reaction by-product arising
from tryptophan indole ring was revealed, Cys moiety was found
to not participate in the reaction, except in the case of a reduced
disulfide, which formed a dithioacetal.
Using similar precursors – electron-rich aniline derivatives –
Tanaka et al.524 could demonstrate the potential of in situ
obtained imines as fluorogenic probes for tyrosine labelling.
While the educts, as well as the imine derivatives, exhibited
weak or no fluorescence, the addition products had a signifi-
cantly higher (more than 100-fold) level of fluorescence.
In the successive study, the same group has expanded this
approach to presynthesised cyclic imines completely excluding
the need for using an excess of highly reactive formaldehyde.525
Although, the authors have clearly demonstrated the applic-
ability of their methodology in water at room temperature over
a wide pH range (pH 2–10) on a set of model phenols, no
example of peptide or protein conjugation has been given.
1.6.5 Dicarboxylates and dicarboxamides. As early as 1969,
the reaction of electron-rich arenes with acyclic diazodicarboxylates
was reported by Schroeter (Fig. 59a).526 Numerous examples of
electron-deficient diazodicarboxylates were established in further
studies being mainly focused on their synthetic usefulness for
electrophilic amination in organic solvents in the presence of
activating protic or Lewis acid additives.527–534
However, these highly reactive reagents decompose rapidly in
aqueous media, which makes them not suitable for bioconjuga-
tion.535 On the other hand, corresponding diazodicarboxyamide
reagents are too stabilised and do not react with phenols in
aqueous media.535 Cyclic diazodicarboxyamides like 4-phenyl-
3H-1,2,4-triazoline-3,5(4H)-dione (PTAD) were recently reported
by Barbas and collaborators and represent a good compromise
between reactivity and stability of diazodicarboxyl-containing
reagents.536,537 Diazodicarboxylate-mediated tyrosine conjuga-
tion is applicable over a wide pH range, however the highest
labeling eﬃciency was observed at pH 7–10.536 A versatile class of
stable PTAD precursors, possessing different functional groups,
was developed and applied for a selective tyrosine conjugation
(Fig. 59b). Their utilisation implies prior to use oxidation with
1,3-dibromo-5,5-dimethylhydantoin and the addition of a small
amount of TRIS (2-amino-2-hydroxymethyl-propane-1,3-diol)
during the step of conjugation. The latter is of crucial impor-
tance for the coupling selectivity, for it is hypothesised to serve as
a scavenger of a putative isocyanate by-product of the PTAD
decomposition, which is promiscuous in labelling.
The non-selective labelling of other aromatic side chains of
proteins is the Achilles’ heel of the vast majority of approaches
Fig. 57 Selective tyrosine labelling of BSA (pdb: 3V03) by 4-formylbenzene
diazonium hexafluorophosphate (FBDP) described by Barbas et al.519 for
installing a bioorthogonal aldehyde functionality.
Fig. 58 Three-component Mannich-type selective modification of the
Y154 Tyr residue of a-chymotrypsinogen A (pdb: 1EX3) by a rhodamine
dye, described by Francis et al.521
Fig. 59 Reaction of electron-rich arenes with azodicarboxyl compounds
(shown in green). (a) First example described by Schroeter in 1969.
(b) Conjugation of an HIV entry inhibitor aplaviroc (APL) containing a cyclic
diazodicarboxamide derivative – 4-phenyl-3H-1,2,4-triazoline-3,5(4H)-
dione (PTAD) – with the IgG antibody demonstrated by Barbas.537
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described for tyrosine labelling. Careful tuning of reaction
conditions is important for achieving appropriate levels of
selectivity. In some cases where purely chemical distinction of
reactivity of amino acid moieties is not feasible, catalysis on the
basis of molecular shape rather than local environment can be
used to induce selectivity. This concept is routinely exploited
by enzymes and allows enabling reactivity that would otherwise
be kinetically impossible. In 2010, Popp and Ball used dirho-
dium metallopeptide catalysts for selective conjugation on
tyrosine and tryptophan using the concept of the proximity-
driven mechanism (see Section 5).454 In the following year,
Silverman et al. have demonstrated a DNA-catalysed approach
for selective labelling of tyrosine, although only on small
peptide substrates.538
1.7 Arginine
With a pKa value above 12, arginine (Arg, R) is mainly presented
in its protonated form in acidic, neutral, and even most basic
environments. Eﬀective delocalisation of a positive charge
between nitrogen lone pairs and the double bond favours the
formation of hydrogen bonds539,540 and makes the guanidinium
side chain of arginine the least acidic cationic group among all
20 natural amino acids (Fig. 60).541
However, the pKa value of arginine was found to vary
significantly in themicroenvironments within certain proteins,542,543
allowing, in terms of Leitner and Lindner,544 the grouping of
arginines in ‘‘exposed’’ or ‘‘partially buried’’ residues, basing
on the diﬀerence of their reactivities.
Most of the described approaches for arginine labelling and
modification exploit the chemistry of a-dicarbonyl compounds.
For instance, introduced by Takahashi545 as an arginyl reagent,
phenylglyoxal has since been applied for the study of complex
systems in the past decade.546–550 The reaction occurs under mild
conditions and consists of two steps: first addition of phenylglyoxal
resulting in the formation of hydrolytically instable imidazolidine
diol, and the second step results in a relatively stable addition
product (Fig. 61).
Substituted phenylglioxal analogs, such as p-hydroxyphenyl-
glyoxal, p-nitrophenylglyoxal and 4-hydroxy-3-nitrophenylglyoxal,
p-azidophenylglyoxal (APG) were reported for spectrophoto-
metric and cross-linking study of the modification of arginine
in proteins.551–555 None of these linkers have however been used
in bond-forming conjugation. Because phenylglyoxal, like
glyoxal, reacts with e-amino groups at a significant rate,545 many
efforts were made to increase its selectivity towards guanidinium
residue. Cheung and Fonda have studied the effect of buffers
and pH on the reaction rate556 and found that the reaction of
arginine is greatly accelerated in bicarbonate–carbonate buffer
systems, possibly due to the stabilisation of the obtained diol.
Geminal diones – namely 2,3-butanedione (introduced by
Yankeelov)557,558 and 1,2-cyclohexanedione (introduced by
Itano)559 – are another well-characterised reagents for the
modification of Arg residues. The reaction progresses through
the pathway that is similar to the phenylglyoxal addition.
However, it was not until the observation that borate had a
significant effect on the selectivity of the reaction that the use
of this reagents became practical.560,561 The presence of borate
in the solution allows shifting of the equilibrium during the
addition to a guanidine moiety through the stabilisation of
reversibly obtained diol (Fig. 62).
In 2005, using this approach, Lindner and colleagues have
described a method for the selection of arginine-containing
peptides from a tryptic digest of the model proteins (BSA,
lysozyme, ovalbumin) by a solid phase capture and release.562
First, arginine containing peptides presented in the digest were
covalently modified on the guanidine moiety with 2,3-butanedione
and phenylboronic acid under alkaline conditions. Polymeric
materials allowing the immobilisation of phenylboronic acid were
then used to capture the arginine-peptides on a solid support while
washing away all not covalently bonded arginine-free peptides.
Finally, the arginine-peptides were cleaved again from the boronic
acid beads due to the reversibility of the reaction. Photoactivable
bifunctional reagents for cross-linking of arginine moieties have
been elaborated by Ngo et al. and Politz et al. to study enzymes with
an arginine at their active sites.555,563
Arginine-specific PEGylation of lysozyme using polyethylene
glycols containing an a-oxo-aldehyde motif in borate buﬀer was
recently reported by Gauthier and Klok564 and represents mild
and selective method for protein modification (Fig. 63). Other
methods described to date565,566 possess selectivities, which are
not suﬃcient (especially in the presence of Lys moieties) to
consider them as suitable for bioconjugation.
Fig. 60 Protonation of the arginine side chain at neutral pH.
Fig. 61 Reaction of phenylglyoxal with the arginine moiety (reaction
condition: 0.2 M N-ethylmorpholine acetate buﬀer, pH 7–8).
Fig. 62 Reaction of 2,3-butanedione with arginine residues of Carboxy-
peptidaze A (pdb: 1HDU) in the presence of borate described by Riordan.560
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1.8 Aspartic and glutamic acids
Carboxylic acid groups can be found in protein structure either
on its C-terminus, or as side chains of Asp and Glu. Due to the
low reactivity of carboxylate in water, it is usually diﬃcult to
selectively conjugate proteins at these moieties. Carboxylic acid
should thus generally be converted to a more reactive ester by
means of so called activating reagents.
For more than a half century, carbodiimide-mediated activation
is the most extensively used methodology for the modification of
free-acids in protein.567,568 The reaction of carbodiimides with
protonated carboxyl groups yields activated acylisoureas, which
then react smoothly with a variety of nucleophiles, namely amines
(Fig. 64).569 It is important to utilise weakly basic amines, that
remain deprotonated and thus reactive at pH below 8.0, to avoid
protein cross-linking occurring at higher pH values. For this reason,
weakly basic hydrazides are often reagents of choice in coupling
reactions with activated carboxylic acids.570 Although water-
insoluble carbodiimides (DCC, DIC) still continue to be useful for
acid-selective protein conjugation,571,572 most current reports
exploit water-soluble carbodiimides such as 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (EDC). Developed by Sheehan and
Hlavka573,574 these carbodiimides first proved their especial useful-
ness as zero-length cross-linking reagents to study proteins.574
Subsequent studies were devoted for the application of carbo-
diimides for quantitation of accessible carboxyl groups in
proteins,567,568,575 preparation of antigenic conjugates,576 and
protein immobilisation.577
As mentioned previously, the upper limit for the optimal pH
of carboxylate conjugation is defined by the reactivity of free
amino groups present in protein. The lower limit is mainly
determined by aqueous stability of the activating reagent. Borders
and co-workers578 studied the stability of EDC in aqueous solution.
It was found that EDC has a T12 of 37 hours (pH 7.0), 20 hours
(pH 6.0), and 3.9 hours (pH 5.0) in 50 mM MES buﬀer at 25 1C;
in the presence of 100 mM glycine, the T12 values were
15.8 hours, 6.7 hours, and 0.73 hours respectively. This sup-
ports the optimal pH for acid-selective conjugation to be in a
range from 6.0 to 7.0. NHS (or its water-soluble analogue sulfo-
NHS) is often included in coupling protocols to improve
eﬃciency or to create a more stable intermediate. Possible
side-reactions involving activating reagents were recently
reviewed by Valeur and Bradley.579
Woodward’s reagent K (N-ethyl-5-phenylisoxazolium-3 0-
sulfonate)580 and analogous substrates were used as activating
reagents of carboxyl groups for synthetic purposes. Bodlaender
et al.581 used N-ethyl-5-phenylisoxazolium-3-sulfonate, the N-alkyl
derivatives of 5-phenylisoxazolium fluoroborate, to activate
carboxyl groups on trypsin for subsequent modification with
methylamine or ethylamine.
Lastly, several studies revealed unexpected examples of
carboxyl group modification with reagents usually reacting far
more eﬀectively with other nucleophiles. For instance,
p-bromophenacyls and iodoacetamides have been found to
selectively alkylate carboxylic acid moieties of pepsin and
ribonuclease T1 respectively.582–584 However, the applicability
of these reagents is not general and is appropriate on specific
substrates only.
1.9 Methionine
In spite being often considered a rather simple target for
chemical modification (mainly through the oxidation and the
reaction with a-halo acetic acids and their derivatives),585,586
only a handful of conjugation methodologies involving methio-
nine (Met, M) were described up to the present.
All approaches described in literature exploit alkylation of
Met residues in acidic media. Although many nucleophilic
functional groups present in proteins can react with alkylating
reagents, at low pH all of them except methionine exist in
protonated forms, which greatly decreases their reactivity.587
Consequently, alkylations of other nucleophilic functional
groups, such as thiols, are commonly conducted at high
pH,400 while methionine is the only functional group in proteins
able to react with alkylating reagents at low pH.
Basing their research on pioneering studies being done
by Toennies in the 1940s,589,590 Kramer and Deming have
recently reported a reversible chemoselective labelling of
methionine in peptides and polypeptides.588 Treatment of the
model peptide (PHCRKM) with alkylating reagents of diﬀerent
structures in 0.2 M aqueous formic acid (pH 2.4) gave a single
product, where only the Met residue was alkylated. This result-
ing sulfonium salts can readily be dealkylated by addition
of pyridine-2(1H)-thione (PyS) to give the starting peptide
as the sole product along with the alkylated PyS byproduct.
The removal reaction was found to be selective and allows
selective dealkylating using concentrations of PyS that do not
react with the disulfide bond in cystine under identical condi-
tions (Fig. 65).
Fig. 63 Selective PEGylation of lysozyme’s arginine side chains (pdb:
2LYZ) described by Gauthier and Klok.564
Fig. 64 (a) Carbodiimide-mediated activation of the carboxylic acid side
chain of glutamate. (b) Relevant examples of activating reagents.
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2. N-terminal conjugation
2.1 a-Amino groups
The most important thing to note about N-terminal amino groups
is that these are the only primary amines present in the protein
structure that possess an adjacent amide bond in a-position, which
slightly influences their reactivity. Consequently, the majority of
classical methodologies exploit this peculiarity of the N-terminus.
2.1.1 Classical approaches. As rather unpolarizable nucleo-
philes, amines react preferentially with hard electrophiles like
acid anhydrides and acyl halogenides.591 The anchimeric influ-
ence of the adjacent amide bond consists in the lowering the
pK value of the amine by electron withdrawal. Consequently,
this makes the discerning of N-terminal amino groups from the
e-amino groups of Lys residues achievable by working at a pH
close to their pK values, i.e. under slightly acidic conditions.
That is, virtually all methodologies described in the Section 1.1
of this review are, to some extent, applicable for selective
labelling of N-terminal amino groups of the proteins.
In the classical work on acetylation of the growth hormone,
Reid592 has for the first time demonstrated the possibility of
selective modification of N-termini, if acetylation is performed with
a relatively small amount of acetic anhydride. Further development
of this approach has in several protocols for selective labelling
of a-amino groups of proteins,3,593 peptides,594,595 and pro-
teomes.596–598 Under optimal reaction conditions, the use of a
5-fold excess of amine-reactive reagent in PBS (pH 6.5) at 4 1C,
high levels of selectivity can be achieve after 2–24 hours of
reaction. However, the preference for terminal amino groups
achieved by control of pH is rather limited, mainly owing to the
fickleness of the pKa of the amino group depending on the
microenvironment and reaction conditions. Consequently,
more proficient methods that rely upon increased chelating
ability of N-termini,599 direct participation of the adjacent side
chains or peptide bond,600,601 were developed and represent to
date preferential approaches for bioconjugation.
2.1.2 Ketene-mediated conjugation. A method for selective
N-terminal modification of proteins by ketenes was introduces
by Che and co-workers602 and consisted in N-terminal ligation
of peptides through oxidative amide bond formation using
the ‘‘[Mn(2,6-Cl2TPP)Cl]/alkyne/H2O2’’ systems. Initially, the
method was tested on a set of six peptides and demonstrated
its applicability. However, inevitable oxidation at Cys and Met
residues hindered the application of the protocol in the field of
bioconjugation. Only after having conducted the mechanistic
studies of this approach, the authors have realised that ketenes
generated in situ were the key intermediates accounting for the
reactivity; therefore prior preparation thereof would allow for
refraining from the need to use an oxidant. In the publication
to follow, Che603 has introduced a general approach for the
modification of N-terminal a-amino groups of a series of
proteins and peptides using an isolated alkyne-functionalised
ketene (Fig. 66). Interestingly, in contrast to classical approaches,
increasing the pH of the reaction mixture did not significantly
aﬀect N-terminal selectivity of conjugation. For comparison, the
ketene reagent was side-by-side benchmarked with a corresponding
NHS-ester. Remarkably, much poorer N-terminal selectivity was
obtained for all studied peptide substrates when the NHS ester was
used. The reason for this impressive specificity of ketenes, however,
remains unelucidated.
2.1.3 Transamination. It was after the success of the con-
version of glyoxyloyl groups into glycyl groups (see Fig. 75)604
that Dixon and co-workers realised that if a terminal Gly residue
can bemade by transamination then a terminal residue of any kind
might be transformed into a corresponding carbonyl-containing
residue by transamination. These introduced carbonyl groups are
not naturally occurring functionalities in proteins and can therefore
be used as unique loci of attachment for synthetic groups through
the formation of hydrazone or stable oxime bonds.605,606
Inspired by the pioneering works of Metzler and Snell,607
and Cennamo and collaborators608,609 on the transamination of
simple amino acids and peptides under harsh conditions
(heating at 100 1C and pH 5.0), Dixon and Moret610,611 devel-
oped a method for mild transamination in the presence of
copper(II) salts, which allowed the reaction to pass at room
temperature (Fig. 67). The isomerisation of the imine generated
in situ by catalysed 1,3-proton shift transfer is the key step of the
transformation which defines both its direction and the reaction
rate. It is clearly the activation of a-protons of N-terminus by the
Fig. 65 Selective reversible modification of a 6-amino-acid peptide
(PHCRKM) via methionine alkylation reported by Kramer and Deming.588
No reactions with other amino acids were detected.
Fig. 66 Selective labelling of lysozyme (pdb: 2LYZ) described by Che.603
Moderate-to-high level of selectivity towards N-terminal residue (K1)
was achieved in the presence of 5 other in-chain lysines (LYS-13, LYS-
33, LYS-96, LYS-97 and LYS-116). The ketene was synthesised from the
corresponding acid by a two-step protocol: transformation into a mixed
anhydride (oxalyl chloride, DCM) followed by the transformation thereof
into ketene upon the reaction with a base (TEA, THF).
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
09
/2
01
7 
12
:4
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 5495--5551 | 5523
adjacent peptide bond and the metal ions that makes this
reaction specific to a-amino groups. Interestingly, Dixon reports
that no traces of the reaction of lysine side chains were ever
observed.600
Quite a wide range of reaction conditions has been tested
ever since. The discovery that pyridine612 and acetate613 greatly
accelerated the transamination of amino acids led to a slightly
milder reaction conditions, which however were still too harsh to
maintain the folded structure of most proteins, and were there-
fore more appropriate for sequence-analysis applications.614
Only recently Francis and co-workers601 have re-examined
Cennamo’s approach608 of amino acid transamination in the
presence of pyridoxal-5-phosphate (PLP, vitamin B6) at 100 1C
and found much milder the reaction conditions whenmodifying
the N-terminal residues of peptides (65 1C for reaction to be over
in 2 hours; 25 1C to achieve a complete conversion in 24 hours).
Screening experiments on diﬀerent N-terminal amino acids of
the peptides indicated that the aldehyde structure strongly
influenced the reaction eﬃciency. Amusingly, known for more
than 50 years PLP emerged as the most eﬀective aldehyde among
dozens being screened, aﬀording the highest yields at milder
reaction conditions.
The mechanism of PLP-catalysed transamination is depicted
in Fig. 68. The reaction of PLP and N-terminal amine results in
forming of a Schiﬀ base aldimine (a). Then the a-proton the
amino acid transferred to the 40 position of the pyridoxal unit
(b and c). Finally, hydrolysis of the obtained ketimine leads to
the desired a-ketoacid and pyridoxamine phosphate (d). Quinoid
is an important intermediate for the transformation of aldimine
to ketimine and can be found in all transamination reagents
described to date.
Under optimal reaction conditions: 10–50 mM protein and
10–50 mM PLP at 37 1C in PB (pH 6–7), a complete conversion is
generally achieved after 2–24 hours. The resulting keto-proteins
are generally rather stable and can be concentrated, stored, or
lyophylised without any specific precautions.615 An example of
transamination-conjugation methodology was demonstrated
by Francis in the initial publication on selective labelling of
an N-terminal glycine residue of horse heart myoglobin and
enhanced green fluorescent protein (EGFP, Fig. 69).601
Although the side chain of the N-terminus does not participate
directly in the transamination mechanism, the reaction rates were
found to vary significantly depending on the amino acid in the
N-terminal position.616 Generally, the majority N-terminal amino
acids provide high yields of the desired transaminated products;
however, some residues (His, Trp, Lys, and Pro) generate adducts
with PLP itself, while other are incompatible with the technique
because of known side reactions (Ser, Thr, Cys and Trp) or
complete inertness (Pro).
In the attempts for the investigation of transamination
reaction scope and limitations, Francis and collaborators have
prepared an 8000-member one-bead-one-sequence combinatorial
peptide library in which the three N-terminal residues were
varied.617 Interestingly, the Ala-Lys (AK) motif was found to favour
especially the transamination yields (the Lys residue is hypothe-
sised to accelerate the isomerisation step of 1,3-proton shift acting
as a general base). To demonstrate this, labelling of the Type III
‘‘Antifreeze’’ Protein and its mutant presenting the AKT sequence
on the N-terminus were side-by-side benchmarked. At every time
point analysed, the AKT terminus outperformed the wild-type one
(GNQ) at diﬀerent concentrations of PLP.
Although mild reaction conditions of PLP-mediated trans-
amination render it amenable for the modification of intact
proteins,618 the yields are generally not high and elevated
temperatures are usually required, which largely limits the
practical applicability of the approach. Given this situation,
Francis and co-workers619 have utilised above-described com-
binatorial approach to identify another transaminative agents. As
a result, N-methylpyridinium-4-carboxaldehyde benzenesulfonate
Fig. 67 General scheme of the transamination reaction activated by
metal ions (typically Cu2+ and Ni2+).610 Principal steps of the reaction
mechanism: (a) generation of the imine; (b) isomerisation of the obtained
imine by proton removal; (c) hydrolysis of isomeric imine to generate
transaminated reaction partners.
Fig. 68 Structure of PLP and mechanism of PLP-mediated transamina-
tion. Reaction pathway consists of (a) condensation reaction between
pyridoxal and the amine; (b and c) tautomerisation of the obtained
aldimine being favourable because of a much lower intrinsic pKa values
of a-proton (shown in blue); (d) hydrolysis of the resulting ketimine,
accompanied by decarboxylation in the case of aspartic acid (R =
–CH2COOH).
601
Fig. 69 Site-specific N-terminal labelling of EGFP (pdb: 2Y0G). Proteins
possessing N-terminal carbonyl groups obtained by in the first step PLP-
mediated transamination were labelled with hydroxylamine probes in the
second step.601
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salt (Rapoport’s salt, RS, Fig. 70) was identified as a highly
eﬀective alternative to PLP. Furthermore, this was found to be
particularly eﬃcient for glutamate-rich sequences.619,620 The
fact that several antibody isotypes dispose at least one
glutamate-terminal chain makes RS particularly amenable for
their selective conjugation. Remarkably, the diﬀerence of trans-
amination reaction rates on Glu- and non-Glu polypeptides was
significant enough for selective labelling of only the heavy
chain of immunoglobulin G1 (containing the N-terminal Glu
residue), while leaving unmodified the light chain. This was
assigned to be due to the higher steric hindrance of the already
less-reactive substrate (N-terminal Asp). To ensure these results
an IgG1 mutant possessing Asp–Asp–Ser sequence on both
chains was prepared. Indeed, this underwent the modification
of both sites when exposed to RS. Facing another recognised
drawback of Francis methodology, namely low efficiency for
bulky amino acid termini (Leu, Ile, Val), Zhang et al.621 have
elaborated an efficient PLP analogue, FHMDP (Fig. 70), that
demonstrated much higher efficiency in transamination
thereof.
The above-mentioned transformations provide just a few
examples of the rapidly growing field of transaminative modification
of proteins. Recent advances have also resulted in elaboration of
general approaches for protein immobilisation (Fig. 71),15,622 dual
fluorescent modification of periplasmic solute binding proteins,623
protein PEGylation and PEG-like conjugation (e.g. OEGMAtion),624
preparation of phage conjugates,625,626 N-terminus proteomics,627,628
enabling Wittig629 and Pictet–Spengler ligation on transaminated
proteins.630,631
2.1.4 2-Pyridinecarboxyaldehydes (2PCA). A promising
approach for one-step N-terminal selective modification of
proteins using 2-pyridinecarboxyaldehyde (2PCA) derivatives
was recently reported by Francis and co-workers.632 Because of
its structural similarity to pyridoxal-5-phosphate and Rapoport’s
salt, 2PCA was occasionally discovered by the authors during a
screening of various aldehyde reagents for their reactivity in
transamination reaction (see Section 2.1.3).
Rather than demonstrating any ability to transaminate, 2PCA
exclusively showed conversion to a pair of cyclic imidazolidinone
diastereomers upon reaction with model peptides. The key step
of the reaction mechanism is a nucleophilic attack of the
adjacent amide nitrogen on the electrophilic carbon of the
initially formed N-terminal imine (Fig. 72a). The presence of
nitrogen heterocycles (namely pyridines) was found to be crucial
for eﬃciency of this stereoelectronically disfavored condensation.
It is noteworthy that Lys residues are unreactive in such a pathway,
because of the lack of a neighbouring amide group suitable for
cyclisation and higher pKa values compared to a-amino groups.
Furthermore, this methodology was also found to be compatible
with the presence of free in-chain cysteines. This approach can
therefore be considered as an orthogonal to other Lys-selective (see
Section 1.1) and Cys-selective methodologies (see Section 1.3).
2PCA-mediated conjugation was found to be generally
applicable for protein labelling (the authors demonstrated its
application on a broad set of 12 diﬀerent proteins including
RNase A; Fig. 72b) except for N-acylated proteins (no imine
formation) and peptides containing proline in position 2 (no
cyclisation of the formed N-terminal imine).632 The resulting
imidazolidinone-containing conjugates are generally moderately
stable and decompose to starting protein by about 20–30% after
12 hours of incubation at 37 1C (in case of RNase A). This may
limit the suitability of this methodology for several applications
where stability of generated conjugates is crucial; however, the
substrate variation could resolve the issue and such efforts are
underway.
2.2 Serine and threonine
In 1960 Waller and Dixon have described the first procedure for
selective N-terminal modification of peptides. It consisted of
preparation of corticotrophin selectively acetylated on its terminal
serine.633 Although being possible only under highly denaturing
conditions of alkali exposure, the approach allowed for a sponta-
neous intramolecular O - N acyl transfer634 on the N-terminal
Ser residues, while O-acetyl groups of in-chain Ser, Thr and Tyr
residues were hydrolysed. The general idea of overcoming the
Fig. 70 PLP-analogues used as transamination agents: Rapoport’s salt619
and FHMDP.621
Fig. 71 Patterning of PLP-transaminated streptavidin (pdb: 4BX5) on
aminooxy terminated polymer films.15
Fig. 72 N-terminal proteinmodification using 2-pyridinecarboxyaldehydes
(2PCT) reported by Francis et al.632 (a) Mechanism of the reaction of
between N-terminal amino group and 2PCA. (b) Modification of native
RNase A (pdb: 7RSA).
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entropy barrier of an otherwise slow intermolecular process by
bringing two reacting partners together through a covalent link-
age to initialize an intramolecular reaction has been later trans-
formed into a large variety of selective modification reactions.
2.2.1 O - N shift of oxazolidines. 35 years after the early
publication of Waller and Dixon,633 Liu and Tam635–637 have
extended the applicability of O - N acyl transfer mediated
methodologies by developing an approach to the chemical
ligation of N-terminal serine, threonine, and cysteine unprotected
peptide segments with no need of using protecting groups. In order
tomake their methodology widely applicable, the authors proposed
a general way to introduce an aldehyde function onto C-terminus
by enzymatic coupling of a masked aldehyde, followed by chemical
hydrolysis of the obtained intermediate.635 The key step of the
process is the formation of the peptide bond through an intra-
molecular rearrangement between the two closely neighbouring
carboxyl and secondary amino groups of formed of oxazolidine
(in the case when Ser and Thr residues are involved) or thiazo-
lidine (in the case of Cys residue, see Section 2.3.2) (Fig. 73).
However, only in case when Cys-peptide was involved the reac-
tion was found to be clean and no side products were observed.
In contrast, when Thr- and Ser-peptides were used, it required
refinement to ensure better yields.636
Although this methodology has demonstrated its high
potential for the ligation of unprotected peptides,635,638,639 the
generation of a ‘‘non-native’’ heterocyclic fragment at the site of
ligating the two peptides made it extruded almost completely by
other ‘‘native ligation’’ approaches; notably, by a similar mechan-
istically native chemical ligation (NCL) (see Section 2.3.1).
2.2.2 Periodate oxidation. A mild version of serine and
threonine modification implies their prior conversion into
glyoxyloyl derivatives via periodate oxidation first described by
Fields and Dixon640 and later transformed into a general method
for site-directed modification of proteins with N-terminal Ser or
Thr by Geoghegan and Stroh.641
Based on the periodic acid mediated oxidation,642 the reaction
occurs only when there exists the target site for the periodate to form
a cyclic intermediate, that is to say, when the N-terminal residue is
represented by a serine or a threonine, or when hydroxylysine is
present (rarely occurring in proteins). Possible side reactions include
oxidation of the side chains of Met, Trp, and His. However, the
potential for side reactions can be diminished by using very low
periodate-to-protein molar ratios, as demonstrated by Geoghegan
and Stroh in their experiments on two model peptides, SIGSLAK
and SYSMEHFRWG, and with recombinant murine interleukin-1a
(an 18 kDa cytokine with N-terminal Ser, Fig. 74),641 or by
conducting the oxidation at neutral pH.643
As in the initial publication of Geoghegan and Stroh,641
obtained glyoxyloyl can serve as the locus for further chemical
modification involving aldehyde-selective reactions (e.g. through
the formation of stable oxime, hydrazone or previously described
oxazolidine moieties).605,606 Robin and colleagues have demon-
strated the possibility of using this two-step methodology for
assembling two unprotected protein fragments: oxidised to
glyoxyloyl-containing and hydrazide peptide derivatives.644 Rose
and co-workers645 exploited the reactivity of generated glyoxyloyls
towards O-alkyl hydroxylamine derivatives to synthesize a penta-
meric form of the cholera toxin subunit B.
Further investigation of periodate oxidation allowed its
promoting for site-selective tagging, PEGylation, preparation
of protein conjugates, protein capture and synthesis of large
protein dendrimers.643,646–651 It is worth mentioning that periodate
oxidation is incompatible with a number of protein classes. For
instance, glycoproteins will undergo periodate-based cleavage of
polysaccharide chains as a side reaction pathway.652
Lastly, glyoxyloyles can easily be transformed into corres-
ponding amines via transamination reaction in the presence of
copper(II) or nickel(II) salts.604,610,653 The reaction mechanism
as well as need for both essential components of the system:
the acceptor of the glyoxyloyl (usually aspartic acid or glycine)
and the cation of a heavy metal are explained in Fig. 75. Despite
being of moderate interest for bioconjugation by itself, this
approach has initiated the development of a more general
methodology for selective N-terminus modification – transaminative
conjugation (Section 2.1.3). The reader is directed to a recent review
by El Mahdi and Melnyk654 for a complete overview of the glyoxyloyl
transformations in bioconjugation.
2.2.3 Phosphate-assisted ligation. Conceptually catching
phosphate-assisted ligation at serine and threonine was
recently reported by Payne and Thomas.655
The inherent reactivity of an N-terminal phosphorylated Ser
or Thr residues was demonstrated to significantly facilitate the
amide bond formation with a range of C-terminal peptide
Fig. 73 General scheme of the ligation strategy proposed by Liu and
Tam.635 A model 50-residue peptide was obtained in good yield in ligation
reaction between a 32-mer peptide VVSHFNDCPDSHTQFEFHGTCRFLV-
QEDKPAR containing C-terminal aldehyde function and a 17-mer peptide
CHSGYVGARC(Ac-m)EHADLLA containing N-terminal cysteine; in the
case of Thr- and Ser-peptides, the reaction was moderately eﬃcient.
The peptides structures were simulated using the RaptorX web server.447
Fig. 74 N-terminal serine labelling of recombinant murine interleukin-1a
(pdb: 2KKI) with Lucifer yellow dye described by Geoghegan and Stroh.641
The method is also applicable if N-terminal threonine is present.
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thioesters. Although it is not yet clear what exact intermediate is
formed during ligation, the authors have hypothesised that rapid
acyl migration to the N-terminal amine of a peptide occurs
through the formation of unstable acyl phosphate (Fig. 76).
2.2.4 Indirect approaches. Ligation at Ser/Thr can also be
achieved considering two distinct indirect approaches. Firstly,
as it was demonstrated by Danishefsky and co-workers,656 NCL-
desulfurisation methodology can be used to access threonine at
ligation sites (see Section 2.3.1.4). Secondly, as an alternative to
the NCL-desulfurisation sequence, cysteine obtained during
NCL can be chemically transformed into serine by methylation
followed by activation of the obtained S-methylcysteine by
cyanogen bromide (BrCN, Fig. 77).657
2.3 Cysteine
Generation of N-terminal Cys residue for native chemical ligation
can be accomplished using solid-phase peptide synthesis,659
proteolytic processing,660 or by the spontaneous hydrolysis of
intein fusion protein.661 Moreover, genetically directed, site-
specific incorporation of 1,2-aminothiols handle into proteins
has been recently reported by Chin and associates.662
2.3.1 Native chemical ligation. The very principle of
‘‘chemical ligation’’ was coined by Kent in the early 1990s
and consisted in an approach for covalent condensation of
unprotected peptide segments by the means of ‘‘unique,
mutually reactive functionalities designed to react only with
each other and not with any of the functional groups found in
peptides’’.663 That is, a general method that would enable the
application of chemical tools to the world of the proteins.
However, the original ligation chemistries exploited the reciprocal
reactivity of chemical functions which are not present in native
proteins and thus their prior introducing onto reacting partners is
require and often associated with synthetic diﬃculties. Moreover,
a non-native linkage is generated at the ligation site; therefore,
many scientists remained sceptical about the validity of using
such ‘‘analogous’’ proteins as tools for understanding the mole-
cular basis of protein function.
In 1994, confronted with this criticism, Kent and co-workers664
introduced a versatile approach to the linkage of peptide fragments
using a native peptide bond – native chemical ligation (NCL). Based
on the original principles of the chemical ligation methodology663
and the ability of thioesters to undergo S - N acyl shift
discovered by Wieland et al.,665 NCL allowed to achieve chemo-
selective formation of the amide bond in the presence of
unprotected nucleophilic amino acid side chains as alcohols
Fig. 75 Preparation of S1G mutant of corticotropin-releasing hormone
(GRH) by regioselective transformation of N-terminal serine to glycine.604
Reaction steps: (a) selective serine oxidation by periodate; (b) formation
of imine with amino group of glutamic acid precomplexated with Cu2+
(Cu-Glu); (c) base-assisted isomerisation of imine; (d) hydrolysis of imine,
completed when aspartate and copper ions are removed.
Fig. 76 Hypothesised mechanism of the phosphate-assisted ligation
reported by Thomas et al.655
Fig. 77 Conversion of a Cys into a Ser residue by transforming the former
into a corresponding methyl cysteine and following thereof by CNBr.657
Methionine must be protected by transforming into corresponding sulf-
oxide form, because this is inactive for the CNBr reaction.658
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(Ser/Thr), phenolates (Tyr), free amines (Lys), carboxylates (Glu/
Asp), or other thiolates (Cys) presented in the macromolecule.
By analogy with previously developed O- N acyl shift, the
reversibility of the thioester-thiol exchange in the presence of
an exogenous thiol additive coupled with the capture of the acyl
segment by S - N acyl shift, being possible only in the case
when the latter is brought in the close proximity to an amine in
a N-terminal cysteine thioester intermediate, result in an
exquisite regioselectivity of this methodology. The product
resulting from this S - N acyl shift represents a peptide,
consisting of two fragments linked by a native peptide bond
through a cysteine residue (Fig. 78).
Typically, the reaction performed in PS or PBS buﬀer (pH
7.0–8.5) at 37 1C is complete in less than an hour and with high
yields.666,667 Solubilizing agents such as guanidine hydrochlor-
ide or urea do not interfere with the ligation and are usually
used to enhance the concentration of peptide segments, and
thus increase reaction rate. It is important to prevent the
thiolate of N-terminal cysteine from the oxidation resulting
in a disulfide-linked dimer, which is unreactive in the ligation.
A reductant (e.g. TCEP) or an excess of thiol corresponding to the
thioester leaving group (4–5%, vol/vol) is generally added to keep the
Cys residues in reduced form. Moreover, the latter largely increases
the overall rate of NCL by reversing the first step of transesterifica-
tion for in-chain intermediate adducts deprived from the possibility
to undergo S- N acyl shift and to generate a stable amide bond.
The first step in synthesizing a protein by NCL generally
consists in defining the fragments to be used in the ligation
reactions. Preferentially, naturally occurring AA-Cys motifs
in the native sequence should be chosen as the ligation sites
(AA stands for any amino acid). Val, Ile, Asp, Asn, Glu, Gln and
Pro represent less favourable choices, because of lower ligation
rates and possible side reactions,666 which, however, can be
accelerated either by transformation of the corresponding
thioesters into selenoesters,668 or by tuning the reaction pH.669
Higher reaction rates were reported to be achievable while
using good thiol-containing living groups, i.e. mildly acidic thiols
such as thiophenol, 4-(carboxymethyl)thiophenol (MPAA), or 5-thio-
2-nitrobenzoic acid (TNB, the reduced form of Elman’s reagent).
These are generally generated in situ by thiol–thioester exchange
from the relatively unreactive peptide- (aCOSCH2CH2CO)-Leu
alkylthioester by adding an excess thereof (1–5%, vol/vol).666
2.3.1.1 Sequential NCL. The complexity of proteins that can
be obtained by NCL technique is limited by the maximum size
of the accessible synthetic peptide segments. Two main
approaches used today for the preparation thereof are: solid
phase peptide synthesis pioneered by Merrifield (allowing the
synthesis of proteins containing up to 50 residues),659 and
recombinant DNA expression elaborated by Lobban et al.670
and Jackson et al.671 These allow for the preparation of peptide
fragments containing up to 50, and up to 150 amino acid
residues respectively.
Sequential native chemical ligation allows further extending
of this limit by means of N-terminal cysteine protected peptides.
Three polypeptide fragments: a peptide1-COSRAr (N-terminal frag-
ment), a protected PG-Cys-peptide2-COSRAr (middle fragment), and a
Cys-peptide3 (C-terminal fragment), are thus assembled in a one-pot
three step synthesis. Firstly, the middle fragment and the C-terminal
fragment are ligated under the classical reaction conditions of NCL.
Then protecting group is removed, uncovering N-terminal cysteine
of the obtained polypeptide (central plus C-terminal fragment),
which undergoes the second NCL with the N-terminal fragment to
give the target protein (Fig. 79).
Since its introduction, sequential native chemical ligation
has demonstrated its general applicability to the preparation of
various complex assemblies. Consequently, several methodologies
compatible with NCL for the protection of N-terminal Cys residues
were elaborated. Themost relevant among them are depicted in the
Table 1.
The reader is referred to a recent review by Melnyk and
collaborators673 for a more complete overview of the sequential
ligation strategies on proteins.
2.3.1.2 Kinetically controlled ligation. The simple observation
that the reaction rate of NCL largely depends on the thioester
Fig. 78 Synthesis of the human interleukin 8 by native chemical ligation
elaborated by Kent et al.664 The ligation reaction occurs between an
unprotected peptide thioester fragment – IL-8(1–33 His-aCOSR), and a
second unprotected peptide possessing a N-terminal cysteine – IL-8(34–72).
First step of thioester exchange results in different thioester-linked intermediates,
among which only the peptide obtained from the corresponding N-terminal
cysteine can undergo following irreversible step of an S–N acyl shift resulting in
obtaining of a native amide bond at the linkage site.
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nature was exploited by Bang et al.675 to introduce a convergent
strategy for the synthesis of native peptides – kinetically controlled
ligation (KCL).
The fact that the kinetics of NCL with alkylthioesters is
significantly inferior of those with arylthioester makes it possible to
control the intrinsic dual reactivity of a bifunctional Cys-peptide2-
COSRAlk so that it would selectively react with a peptide1-COSRAr
and then undergo a classical NCL (i.e. in the presence of
exogenous aryl thiol) with a third Cys-peptide3 to yield an
assembled peptide1-Cys-peptide2-Cys-peptide3 with no need to
use protecting groups. Bang and collaborators have applied this
methodology to assemble a 46-residue protein crambin from six
peptide fragments (Fig. 80).
Further advancing pioneering works done by Botti
et al.686 on in situ acyl migration, KCL methodology has
been recently extended from alkylthioesters to a full class of
O-esters undergoing a spontaneous transformation to pro-
duce a thioester when exposed to a reducing agent through
disulfide bond reduction followed by O - S acyl shift
(Fig. 81).687
Through a thorough investigation Zheng et al.687 have
defined that structures of the O-esters have an important eﬀect
on their reactivity. The authors have side-by-side benchmarked
their methodology with previously described KCL by synthesiz-
ing the same V15A crambin (Fig. 80) by a one-pot one-step
condensation of peptide segments and found its applicability
to this system. Readily available by Fmoc solid-phase synthesis,
Fig. 79 Synthesis of insulin-like growth factor 1 (IGF-1) via sequential
native chemical ligation described by Sohma et al.672 The reversible
protection of the a-amino group of the central peptide fragment
IGF(18–47) prevents its self-reaction with the a-thioester moiety present
in the same molecule. Thiazolidine protecting group can be easily
removed by brief treatment with NH2OMeHCl at pH 4. NCL reaction
condition used: PB (pH 6.7), 6M GndCl, 10 mM MPPA, 20 mM TCEP.
Table 1 Chemical functions generally utilised for the protection of N-terminal cysteine during sequential native chemical ligation
Protecting group Deprotection Examples
1 Thz NH2OMe pH 4
IGF,672 HIV-1 Tat,674 crambin,675,676
EPO,677 PYP678
2 Msc679 pH 12 SOD,680 Abl-SH3681
3a Acm682 AgOAc, DTT Crambin,683 DAGK684
4 Mapoc685 hn 4 300 nm hBNP-32685
a Require a preparative-HPLC step before removal, gives lower overall yield compared with Thz.683
Fig. 80 Two final steps of the synthesis of V15A crambin (pdb: 3NIR)
described by Bang and associated.675 The mutation was introduced for
simplifying the prior KCL step of assembling the second peptide. Kinetically
controlled ligation of SAr thioester spontaneously occurs in aqueous media
in the absence of exogenous thiophenol, while native chemical ligation of
SAlk thioester must be accelerated by the addition of 1% PhSH.
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
09
/2
01
7 
12
:4
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 5495--5551 | 5529
these O-ester scaﬀolds can expand the applicability of NCL to
substrates with hardly accessible thioester peptide fragments.
2.3.1.3 Access to C-terminal peptide thioesters
Classical approaches. The preparation of C-terminal a-thioesters
involved in native chemical ligation is often associated with
synthetic diﬃculties. Being especially reactive species, they
either have to be introduced at the end of the synthetic pathway
or be kept in a hidden form of thioester surrogates possessing
higher stability.
Despite its recognised drawbacks due to hazardous acid
treatment often leading to undesired side-reactions, the protocol
of in situ neutralisation for Boc-based solid-phase peptide synthesis
represents the most eﬀective approach for the preparation of
peptidyl thioesters.666,688–690 Alternatively, the Fmoc synthesis
approach was investigated691–693 and found to be favoured
when synthesizing phospho- and glycopeptides.
Expressed protein ligation (EPL). Introduced by Muir et al. in
1998,694 EPL represents another approach for the preparation
of a-thioesters. It allows for obtaining the recombinant protein
thioester by thiolysis of an intein fusion protein and thus
enables a large pool of elaborated recombinant protein techniques
for NCL. The reader is directed to several recent reviews of this area
on chemical research for more details.695,696
X - S acyl-transfer. An elegant approach for keeping
thioester in a relatively inert ‘‘hidden’’ form ready to be uncovered
when required was first introduced by Danishefsky and colleagues in
2004 (Fig. 82).697 Several years later, the name ‘‘crypted thioesters’’
was coined by Otaka698 as a general term for such compounds. This
approach is of especial interest, because it enables the assembly of
peptide segments in N-to-C direction, which is rather rare and often
diﬃcult to achieve.673 Indeed, all above-described methodologies
rely on the assembling of polypeptide chain in C-to-N direction: for
instance, the sequential native chemical ligation per se consists of
iterated cycle of ligation-deprotection-ligation. . ., i.e. adding new
peptide fragments onto N-termini after deprotection thereof (see
Section 2.3.1.1).
Synthesis of thioesters in situ from stable amides via N- S
acyl-transfer was demonstrated by Ohta et al.699 who studied
acylated oxazolidinones derived from S-protected cysteine.
These possess a distorted amide planarity provoking so called
ground-state destabilisation700 and, as a consequence, favour
the acyl migration to a deprotected thiolate. Nakahara and
collaborators have studied and elaborated two classes of sec-
ondary amides amenable to the N - S acyl shift at low pH
values: 5-mercaptomethyl prolines701 and N-alkyl cysteamides
(Fig. 83a).702 Oxazolidinones699 and N-sulfanylethylamilides
(SEAlides)703 described by Otaka and collaborators were found
to possess similar aptitude towards N- S acyl-transfer shift at
low pH (for a complete overview of N- S acyl-transfer systems
described before 2010 see review by Kang and Macmillan).704
Erlich et al.705 have recently applied N-alkyl cysteamide-based
approach for the synthesis of 76-residue ubiquitin thioester,
while Otaka and collaborators have demonstrated high
potential of SEAlides by conducting the chemical synthesis of
162-redue active glycosylated GM2-activator protein.706
Almost simultaneously have two research groups reported a
general approach, based on the application of bis(2-sulfanylethyl)-
amides (SAM) as precursors for NCL.707–710 An interesting extension
of the methodology enabling the possibility of triggering the
reactivity of SAM – so called SEAon/off system – has been further
elaborated by Melnyk and collaborators.711 The transition
between reactive (SEAon) and unreactive (SEAoff) states is simply
triggered by mild oxidation/reduction procedures (Fig. 83b).
SEAoff can be easily switched on via TCEP reduction, while the
reverse switching off is achieved by mild oxidation with iodine.
After few seconds, the excess of iodine is decomposed by the
addition of dithiothreitol (DTT). Other amino acid residues
susceptible to oxidation such as methionine or tryptophan are
not affected because of this very short exposure to oxidant.
However, cysteine residues must be protected with tert-
butylsulfenyl groups to remain unaffected. At low pH values
these are not reducible by DTT, allowing thus reliable protec-
tion of cysteines during the cycles of oxidative–reductive SAM
triggering.
Fig. 81 Schematic representation of the O - S acyl shift of O-esters
containing a disulfide bond described by Zheng et al.687
Fig. 82 Principle of ‘‘crypted thioesters’’ demonstrated by Danishefsky
and co-workers.697 Intramolecular O - S migration of acyl residue
resulting in generation of highly active thioester (its ‘‘uncrypted form’’)
occurs only upon reductive cleavage of disulfide bond of reasonably stable
‘‘crypted form’’.
Fig. 83 N- Smigration of acyl residue. The thioester-amide equilibrium
is shifted towards the thioester form at low pH due to the protonation of
the secondary amides. In the presence of 3-mercaptopropionic acid (MPA)
all intermediates produce MPA-thioester. (a) From left to right: reduced
form of Danishefsky’s ester,697 5-mercaptomethyl prolines,701 N-alkyl
cysteamides,702 oxazolidinones,699 and N-sulfanylethylamilides.703
(b) SAMon/oﬀ approach by Melnyk and collaborators.711
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To demonstrate the potential of this newly established and
optimised SAMon/oﬀ system, Melnyk and collaborators have
synthesised 85-residue domain of the hepotocyte growth factor
(HGF 125–209).711
2.3.1.4 Indirect ligation on other amino acid using NCL. In
2001, Yan and Dawson712 have introduced an approach that, for
the first time, allowed virtually conducting NCL at alanine.
While the ligation still occurred at N-terminal cysteine, its
subsequent desulfurisation with freshly prepared RANEYs
nickel produced the native target sequence containing alanine
residue at the ligation site (Fig. 84). This strategy has inspired
the development of a large pool of various ligation junctions that
includes phenylalanine,713,714 glycine,715 valine,716,717 leucine,674,718
threonine,656 serine,657 proline,719–721 aspartate,722 glutamine,723
homocysteine,724,725 methionine (by subsequent S-methylation of
the ligated homocysteinyl product by p-nitrobenzenesulfonate)724
arginine,726 and lysine (a- or e-selective) ligations.727,728
In order to extend native chemical ligation-desulfurisation
approach to these amino acids, a SH-group should be attached
to the carbon atom situated in the b-position to amino group
(in some cases in the g-position). The new building block
containing a b-mercapto-a-amino or g-mercapto-a-amino fragment
is then introduced at the N-terminal position during solid-phase
peptide synthesis or by means of DNA-recombinant technologies.714
Following ligation is conducted under classic NCL conditions: at pH
7.5–8.0 in the presence of TCEP as reducing agent and 1% of
exogenous thiol additive. Finally, the desulfurisation of cysteine gives
a nascent residue of interest (Table 2).
Besides aforementioned reduction on RANEYs nickel, various
milder conditions such as nickel boride,712 Pd/Al2O3,
729 ormetal-free
conditions730,731 were developed to achieve eﬃcient desulfurisation.
More recently, in situ ligation-desulfurisation approach was also
reported.732,733
Desulfurisation-based methodology of the NCL expanding
towards other amino acid junctions have contributed in many
ways to prepare proteins and posttranslationally modified
analogues for biochemical and structural analyses ever since
its introduction. However, despite this broad utility, carrying
out desulfurisation of the linkage site in the presence of other
Cys residues in the protein sequence usually requires using of
Fig. 84 Synthesis of 21-residue cyclic antibiotic peptide Microcin J25 via
NCL-desulfurisation strategy resulting in alanyl-linked polypeptide chain
developed by Yan and Dawson.712 Reaction conditions: cyclisation – Tris-HCl,
6 M GndCl; desulfurisation – NaOAc, pH 4.5, 6 M GndCl, H2 (Pd/Al2O3).
Table 2 Desulfurisation-based NCL methodologies
Entry AA Intermediate Product
1 Ala
2 Phe
3 Leu
4 Thr
5 Val
6 Pro
7 Lyse
8 Lysa
9 Asp
10 Gln
11 Arg
12 Gly
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protecting groups.729,734 Not only does this necessity represent
an undesirable step to protein synthesis, but it also implies
some limitations on the applicability of the approach, mainly
due to the solubility issues.
Developed by Dawson and collaborators735 the protocol for
selective reduction of selenocysteines (Sec, U) in the presence of
cysteine allowed overpassing the need for protection of thiolates
and expanded the already established field of Sec-mediated
native chemical ligations (see Section 2.6).736–739
The sensitivity of Sec peptides to reduction was noted in
several works on selenocysteine ligations,737,738,740 During their
preceding work on the synthesis of seleno-glutaredoxin 3
analogues (Se-Grx3), Dawson and associates741 have observed
this incompatibility of Sec-containing proteins and peptides
with TCEP-assisted native chemical ligation due to the genera-
tion of significant levels of a deselenised side product. In the
publication to follow, the authors have successively applied the
ligation-deselenisation strategy on a model peptide system.
Accordingly, N-terminal Sec-peptide1 (UGLEFRSI-amide) pre-
pared in the form of a diselenide dimer was ligated to the
thioester peptide2 (Ac-LYRAG-SR) (Fig. 85) to produce the
deselenised alanyl-peptide (Ac-LYRAGAGLEFRSI-amide) after
the treatment with 50-fold excess TCEP at pH 5.5. Importantly,
an excess of 200 mM 4-mercaptophenylacetic acid (MPAA) was
needed for the ligation step. MPAA is both served as a catalyst
to activate the alkyl thioester and as mild reducing agent to
generate a small pool of free selenol to facilitate the ligation
reaction.
This selectivity of reduction with TCEP is hypothesised to be
due to the weaker Se–C bond compared with the S–C bond
coupled with higher propensity of selenols to form radicals.742
It should be mention, however, that albeit upon heating,
cysteine can be desulfurised in the absence of a radical initiator
when treated with excess phosphine.743
Selenocysteine-mediated NCL deselenisation procedure
have been recently exploited for selective ligation of selenol-
phenylalanine,744 and g-selenolproline,720 easily transformable
into peptides phenylalanine and proline respectively at the
ligation site by treating Se-containing intermediates with TCEP
or DTT. Analogously to N - S acyl transfer (Section 2.3.1.3),
N- Se acyl shift was recently observed by Adams and Macmillan
and allowed NCL to take place at lower temperatures and on
shorter time scales.745 Corresponding selenoesters can be readily
accessible by direct solid phase synthesis.746
NCL principles of S - N acyl transfer found their applica-
tion in ligation assisted by proximity eﬀect (see Section 5),747
allowing for conjugation of N-terminal residues other that
cysteine by auxiliary-mediated acyl transfer. Furthermore, the
Cys side chain thiolate introduced during NCL can also provide
a synthetic handle for further functionalisation using cysteine-
selective methodologies (see Section 1.2). It was recently
demonstrated by Fang and co-workers that more accessible
than thioesters simple phenyl esters could undergo native chemical
ligation smoothly under the promotion of imidazole.748 Lastly,
recently reviewed by Monbaliu and Katritzky749 Kemp’s template-
mediated thiol ligation,750–758 Tam’s ligation by thiol/disulfide
exchange,759–761 and other auxiliary-driven extensions of native
chemical ligation,762,763 represent significant importance in the
field of protein synthesis and can be considered as appropriate
for bioconjugation.
2.3.2 Thiazolidine formation. Further expanding the
applicability of the reaction of cysteine with formaldehyde
described by Ratner and Clarke,764 Tam and collaborators have
elaborated a method for the selective conjugation of N-terminal
cysteines with aldehydes, resulting in obtaining of stable thia-
zolidines.636,643,765–767 The reaction of 1,2-aminothiols readily
occurs at slightly acidic pH of 4–5, while the concurrent
reaction of free amines with aldehydes results in obtaining
Schiff bases reversibly under the same conditions.
The thiazolidine-mediated ligation was first applied by Tam
and associates to the preparation of peptide dendrimers765,767
by attaching unprotected peptide dendrones containing Cys
residues at their N-termini to a branched core matrix with
aldehyde functions. Botti et al.766 have transformed this
approach to a general method for the preparation of cyclic peptides.
Villain et al. have demonstrated that obtained thiazolidines (some-
times referred to as pseudo-prolines)768 can be selectively cleaved by
adding hydroxylamine derivatives, which react with aldehyde func-
tions protected under the form of thiazolidine to form oximes. The
authors applied this methodology for the covalent capture of
proteins possessing N-terminal Cys or Thr residues (Fig. 86).769
Interestingly, under the same conditions N-terminal Ser residues
reacted only poorly.
Because of the recent advances in the semisynthesis of
proteins and the encoding of 1,2-aminothiols into recombinant
proteins,662,770,771 thiazolidine-mediated conjugation is now experi-
encing a reappraisal of its potential for bioconjugation.772,773 For
instance, Casi et al.772 have exploited thiazolidine formation for
the preparation of antibody–drug conjugates by site-specific
incorporation of a potent drug, containing an aldehyde moiety,
to engineered recombinant antibodies displaying a Cys residue
at their N-terminus, or a 1,2-aminothiol at their C-terminus.772
Lastly, thiazolidines represent one of the most often used
N-terminal cysteine protecting groups for sequential NCL (see
Table 1, Section 2.3.1.1).
2.3.3 2-Cyanobenzothiazoles (CBT). The reaction of 2-cyano-
benzothiazole (CBT) with D-cysteine was first conducted by Field
Fig. 85 Traceless ligation of peptides using selective deselenisation
described by Dawson and collaborators.735
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and collaborators774 for the preparation of synthetic luciferin: a
compound found in various living organisms and responsible
for emitting light after being oxidised by a specific enzyme
luciferase. Ever since its isolation (9 mg from 15 000 firefly
lanterns),775 luciferin enzymatic oxidation has been studied for
the last 50 years.776
The regeneration pathway of luciferin in firefly was found to
be consisted of the condensation of CBT with D-cysteine
(Fig. 87).774 The reaction mechanism underlying this addition
include first attack of cyano group of CBT by cysteine thiolate.
This results in the formation of the electrophilic imidothiolate,
subjected to the second attack by cysteine amino group to form
thiazole structure after the yielding of ammonia gas.
Inspired by these early works, Rao and co-workers777 have
further investigated the reaction of cyano-substituted aromatic
compounds with amino-thiol substrates. They have demonstrated
that benzotriazole motif plays an important role for the activation
of the cysteine addition to a nitrile group. For instance, under
optimal reaction conditions (PBS, pH 7.0–7.5) its replacement by
other aromatic fragment such as picolinonitrile or benzonitrile
largely decreases the reaction yield. All naturally occurring amino
acids are unreactive towards CBT, except for cysteine owing the
highest second-order rate constant among six other tested amino-
thiol substrates (9.19 M1 s1, which is significantly higher than
these of the majority of biocompatible click reactions).778 Finally,
the efficiency and specificity of CBT-based labelling of terminal
cysteine residues was demonstrated on proteins in vitro (Fig. 88) as
well as on cell surfaces.
In the publications to follow, Rao and colleagues have
extended the applicability of CBT towards biocompatible con-
densations to create polymer assemblies in vitro and in living
cells under the control of either pH, disulfide reduction or
enzymatic cleavage.779,780 Yuan et al. have taken advantage of
this approach and developed a method for the determination of
glutathione (GSH) concentration in vitro and in HepG2 human
liver cancer cells.781 Jeon et al.782 have elaborated a CBT-based
18F-probe radiolabelling of N-terminal cysteine-bearing peptides
and proteins. Two labelled substrates: a dimeric RGD-peptide –
[18F]CBTRGD2, and Renilla lucifierase bearing a cysteine at
N-terminus, have been synthesised with excellent radiochemical
yields and shown good in vivomolecular PET imaging efficiency.
Proceeding efficiently at physiological conditions, CBT-mediated
N-terminal Cys conjugation represents a useful alternative to
existing approaches for protein labelling.783
2.4 Tryptophan
2.4.1 Sulfenylation-coupling. Encouraged by early reports
from Scoﬀone and colleagues, who examined the site-selective
modification of the nucleophilic 2-position of the tryptophan
indole ring through electrophilic sulfenylation with various
sulfenyl chlorides,784,785 Payne and collaborators have recently
brought back into life a classical reagent for Trp selective
modification – 2,4-dinitrophenylsulfenyl chloride (DNPS-Cl).786
The authors have demonstrated that, in acidic conditions, all
nucleophilic amino acid side-chains except tryptophane (gives
moderate yields of about 50% after 16 hours) either remained
unmodified, as in the case of serine, threonine and the e-amino
groups of lysine, or were reversibly modified in the case of
cysteine, which forms an easily reducible asymmetric disulfide.
Further thiolytic cleavage of the resulting 2-Trp thioether deri-
vatives with an external thiol nucleophile affords the corres-
ponding 2-thiol Trp derivatives (2SH-Trp, Fig. 89a) in good
yields. Interestingly, being placed on the N-terminus of the
peptides, 2SH-Trp scaffolds were found to enhance the kinetics
Fig. 86 General scheme of covalent capture purification of N-terminal
cysteine containing proteins developed by Villain et al.769
Fig. 87 Synthesis of luciferin by the reaction between cyanobenzothia-
zole (CBT) and D-cysteine.774
Fig. 88 Labelling of Renilla luciferase (pdb: 2PSD) by CBT-based
probes.777 N-terminal cysteine was generated by protease processing of
the fusion protein.
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of the native ligation with peptide thioesters, and could thus
serve as Na acyl transfer auxiliaries (see Section 2.3.1).787
The proposed mechanism for this approach is mechanistically
similar to NCL. It was hypothesised that the reaction would proceed
via an initial step of the peptide thioester transthioesterification
with an indole 2-thiol functionality followed by an S- to N-acyl shift
through a 7-membered ring transition state to generate a native
amide bond. The last step of 2-thiol Trp desulfurisation results in
obtention of a ligated product with only naturally occurring amino
acid residues (Fig. 89b). Although this methodology represents a
clever chemoselective approach for the ligation of completely
unprotected peptide fragments through Trp moiety, the harshness
of the reaction conditions of sulfenylation and desulfurisation limit
it only to peptide substrated and don’t allow its application on
complex biomolecules.
2.4.2 Pictet–Spengler reaction. Another approach for the
ligation of unprotected peptides was proposed by Li et al.788
and exploited the Pictet–Spengler reaction: an acid-catalysed
intramolecular condensation between an iminium ion and an
aromatic C-nucleophile described in 1911.789 This non-natural
ligation (peptides are linked by non-natural bonds) involves
reaction of two peptide partners in acetic acid: one containing a
Trp residue at its N-term and another with a C-terminal
aldehyde function. The latter should generally be introduced
by means of solid-phase peptide synthesis on acetal resin
(described by the same authors).
2.4.3 N-Acyl tryptophan isopeptides. Lastly, an interesting
example of native N-terminal Trp ligation, mechanistically very
similar to NCL (see Section 2.3.1), was recently reported by
Popov et al.790 The key intermediates of this methodology –
N-acyl tryptophan isopeptides – undergo selective acyl transfer
to yield natural peptides. These are, however, not accessible
directly by methods reported so far, which substantially
restricts the applicability of the methodology.
2.5 Histidine
Despite being known for its particular importance for the acyl
transfer in many enzymatic processes,665 histidine has been
rarely used for bioconjugation. The only study describing the
ligation of N-terminal His peptides with activated thioester was
reported by Zhang and Tam.791
Ellman’s regent348 was used to activate the C-terminal peptide
thiocarboxylic acid by forming acyldisulfide derivative, which is
then nucleophilically attacked by N-terminal histidine. Captured
by the imidazole of the N-terminal histidine, the obtained
Nim-acyl intermediate is hypothesised to undergo Nim - Na
shift to form histidine at the ligation site (Fig. 90). However, the
Nim-acyl intermediate has not been isolated and it is quite
possible that regioselectivity is obtained simply because of
anchimeric assistance of the proximal imidazole moiety at the
ligation site.
Interestingly, no sign of coupling reaction has occurred
when a corresponding non-activated C-terminal thiocarboxylic
acid is participating in the reaction instead of the acyldisulfide.
The reaction pH plays an important role on the eﬀectiveness of
the reaction. Only when maintained at slightly acidic values
(pH 5–6) and in the absence of the thiol nucleophiles, would the
imidazolyl moiety of histidine be the sole nucleophile present in
the polypeptide. This methodology has been applied to generate
histidine-containing peptides with yields up to 75%.
2.6 Selenocysteine
Selenium and sulphur belong to the same main group of
elements; therefore, 21st proteinogenic amino selenocysteine
and Cys residue exhibit rather similar properties in terms of
reactivity for bioconjugation.792–794 For instance, both Hilvert’s738
and Raines’s group736 demonstrated that C-terminal peptide
thioesters react smoothly with peptide fragments containing a
N-terminal selenocysteine in exactly the same manner as with
corresponding cysteine analogues. Presumably proceeding
through the same mechanism as NCL (Section 2.3.1), the first
Fig. 89 Ligation–desulfurisation at tryptophan, reported by Payne and
collaborators.786 (a) Electrophilic sulfenylation of Trp in acidic conditions
with DNPS-Cl and the obtention of the corresponding 2SH-Trp derivative.
(b) Auxiliary-assisted native ligation of N-terminal 2SH-Trp peptide (2SH-
WSPGYS-NH2) with a thioester of the peptide Ac-LYRANG-SPh resulting in
12-mer peptide Ac-LYRANGWSPGYS after the desulfurisation step.
Fig. 90 N-terminal histidine labelling described by Zhang and Tam.791
(a) Mechanism of thiocarboxylic acid activation by Ellman’s reagent.
(b) Labelling of bovine parathyroid hormone fragment (14–34, pdb:
1ZWC) with activated tetrapeptide thioacid.
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step of the ligation process consists in the nucleophilic attack
on the thioester by selenolate to give a selenoester intermediate
that subsequently rearranges to give a native chemical bond.
Sec ligation can be chemoselective when conducted at
slightly acidic pH. Low intrinsic pKa values of selenocysteine
(5.2)795 and consequently its higher dissociation level at low pH,
endows this amino acid with unique biochemical properties,
allowing regiospecific covalent conjugation with electrophilic
compounds in the presence of the side chains of all other natural
amino acids including the thiol group of Cys (pKa 8.3). For
instance, the reaction rate with selenocysteine was found to be
1000 fold faster than with cysteine at pH 5.0.736 Moreover, the
lower pH generally suppresses b-elimination of the selenol group
from selenocysteine resulting in the obtaining of unreactive
dehydroalanine.392
Initially, considerable eﬀorts were made to show the applicability
of selenocysteine NCL for the preparation of selenium-containing
derivatives of enzymes and benchmarking activities thereof. Hilvert
and associates synthesised a C38U analogue of bovine pancreatic
trypsin inhibitor (BPTI). Amusingly, the wild-type BPTI and its
artificial analogue folded into alike conformations and demon-
strated similar inhibiting aﬃnity of trypsin and chymotrypsin.738
Raines et al. selected 124-residue ribonuclease A (RNase A) as a
model protein for the investigations.736 DNA recombinant
technology was utilised to prepare a C-terminal thioester fragment
corresponding to residues 1–109, while standard solid phase peptide
synthesis methodology was used to obtain a N-terminal Cys and Sec
peptides corresponding to residues 110–124 (Fig. 91). Just as in the
case of BPTI, the semisynthetic wild-type RNase A and C110U RNase
A presented equivalent ribonucleolytic activities. Further advances in
the field of Sec-NCL have resulted in synthesis and investigations of
other different proteins such as seleno-glutaredoxin,796 azurin,797,798
and thioredoxine reductase.
Ease of the post-ligation transformation of selenocysteine to
alanine (by deselenisation), dehydroalanine (by b-elimination)
or non-natural amino acids (by addition reaction to dehydroalanine,
see Section 1.3.8) became a spur to a further propagation of
Sec-mediated methodologies as very eﬀective tools in rational
design of peptides and proteins. Quaderer and Hilvert799
exploited such transmutations of selenocysteine to access a
series 16-residue cyclic peptides (Fig. 92).
In this initial report, the deselenisation step was conducted
rather harshly (RANEYs Ni, H2), implying that all Cys residues
(if there were any) would have been reduced as well. Recently,
however, Dawson and collaborators735 have demonstrated that
selenocysteine can be chemoselectively deselenated with TCEP
in the presence of cysteines. This allowed overpassing the main
limitation of the NCL-desulfurisation strategy (see Section
2.3.1.4), namely the inability to control regioselectivity of
desulfurisations if several cysteines are present in the peptide
or protein, and yielded in a pool of NCL-deselenisation strategies
for mild incorporation of alanine, phenylalanine and proline
into the ligation site by classic NCL approaches (see Table 2).
Finally, selenocysteine peptides were found to eﬃciently
undergo reverse NCL at acidic pH and thus to be of particular
interest for the generation of thioesters by sequential N - Se
acyl-transfer and substitution of the obtained selenoester by
exogenous thiol (see Section 2.3.1.3).745
Because the incorporations of selenocysteine by the cell
translational machinery are generally very laborious,800,801
selenopeptides are mainly obtained by SPPS.736,737,794
2.7 Proline
The oxidative coupling of o-aminophenols and o-catechols
recently reported by Francis and collaborators802 represents
an interesting approach for selective N-terminal conjugation on
proteins. The strategy consists in prior in situ oxidation of
o-aminophenols and o-catechols to active coupling species using
potassium ferricyanide (Fig. 93a) followed by their reaction with a
protein (Fig. 93a). This approach was shown to work particularly
well with proline (due to increased nucleophilicity thereof) and can
therefore be considered as N-terminal Pro selectivemethodology.802
The key advantage of the approach compared to the majority
of N-terminal selective methodologies is its fast second-order
Fig. 91 Selenocysteine native chemical ligation applied for the prepara-
tion of C110U mutant of RNase A (wild-type – pdb: 7RSA).736
Fig. 92 Synthesis of cyclic 16-resiudes selenopeptides by native chemical
ligation and following transformation thereof to (a) alanine (RANEYs Ni,
H2, TCEP, 20% AcOH); (b) dehydroalanines (H2O2, 10% ACN).
Fig. 93 Selective modification of 1P-GFP (Pro residue is introduced on
N-terminus) with o-aminophenol-PEG reagent (wild-type – pdb: 1GFL).802
(a) In situ oxidation of o-aminophenol derivatite. (b) Reaction of the active
coupling species with N-terminus of 1P-GFP.
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kinetics in a single step transformation, which does not require
prior oxidation of the N-terminus. Free cysteine residues, however,
are also reactive during the oxidative coupling and must thus be
protected, which represents the main drawback of the approach.
3. C-terminal conjugation
Chemical methods for C-termini conjugation are rather scarce.
Definitely, previously mentioned approaches for the conjugation of
side-chain carboxylates (see Section 1.5) can also be applied
eﬀectively to modify the terminal carboxylates. The selectivity,
however, would be the main issue, for up to date there is no
described method for somewhat selective activation of N-terminal
carboxylates by any activating reagent.
Because of the impetuous development of NCL (see Section
2.3.1), requiring C-terminal thiolates as reacting partners for
N-terminal Cys proteins, those became widely accessible, namely
by means of SPPS. A perspective approach, exploiting these
advances was proposed by Goody803 and collaborators, who
developed a protocol for selective transformation of C-terminal
thioesters to corresponding hydroxylamines, enabling thus the
application of aldehyde- and ketone-selective methodologies on
the C-terminus.
On the other hand, the unique position of protein C-termini
has stimulated numerous eﬀorts to target this location, which
resulted in numerous enzymatic and intein-based approaches
for C-terminal-selective protein modification.804–809 These
methodologies are, however, not covered by this review devoted
to chemical methods of bioconjugation.
4. Sequence-selective approaches
Several especially useful methodologies in bioconjugation
exploit not a specific property of the residue, or its peculiar
position in protein, but rather the synergetic eﬀect of a batch of
neighbouring amino acid residues. For instance, an example of
such selectivity is the aforementioned selective modification of
His-AA-Ser and His-AA-Thr peptide motifs (see Section 1.2) by
usually promiscuous activated esters. In this case, the His
imidazolyl side chain located in close proximity to Ser/Thr side
chains increased the reactivity thereof towards electrophiles.
Metal-chelation methodologies are perhaps the most elaborated
among sequence-selective approaches (Fig. 94).810 The oligo-
histidine sequence (usually H6), called His-tag, is known to interact
robustly with transition-metal complexes, including a nitrilotriacetic
acid (NTA) complex of Ni2+, therefore the sequence is widely used for
protein purification by aﬃnity chromatography. Similarly, oligo-
aspartates (most often (D4)n, n = 1–3) were developed for selective
labelling with multinuclear Zn2+ complexes.811,812 The tetracysteine
motif (CCPGCC) was reported to especially effectively chelate
biarsenical dyes such as 40,50-bis(1,3,2-dithioarsolan-2-yl)fluorescein
(FlAsH),5,813 while a similar structural tetraserine sequence (SSPGSS)
was found to be selective for diborate-scaffolds.
5. Proximity-driven modifications
All the above-mentioned methodologies are mainly residue-
specific. That is to say, they exploit specific reactivity of the
functional group of interest or of an assembly of residues. As a
result, bioconjugations of highly nucleophilic Cys, Lys, and Tyr
residues with electrophilic reagents are definitely prevalent
among described methodologies.
The inherent reactivity is rare to be overcome, which largely
limits of the scope of known methods for bioconjugation of the
amino acids possessing low nucleophilicity. However, bringing
the reaction partners into close proximity can accelerate a
reaction thereof, which would not otherwise be possible because
of the presence of other more reactive species. Routinely
exploited by enzymes, this approach enables selectivity on the
basis of the molecular shape rather than reactivity or the local
environment (Fig. 95).
Fig. 94 Strategies for the selective conjugation of proteins based on
metal-chelation: tetracysteine/biarsenical system, oligohistidine/nickel-
complex system, tetraserine–borate system, oligo-aspartate/zinc-complex
system.27
Fig. 95 Schematic representation of the proximity-driven approach for
selective modification of macromolecules. Combining of promiscuous
reactivity of the reactive group (RG, shown in red) with specific molecular
recognition results in specific modification of the functional group of
interest (FG, shown in blue).
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Developed by Hamachi and collaborators in 2006,462 the
post-aﬃnity-labelling approach can be used for the selective
tethering a functional molecule at the proximity of the active site
of enzymes. This method was then used on numerous substrates
and enlarged the scope of selective conjugation especially on
histidine and tyrosine (see Section 1.5.1).462,463,486,814 Despite
these successes, a prevalent limitation of the applicability of the
method due to the possible modification of the residues situated
only in the vicinity of ligand-binding pocket of the target protein
prevents this methodology from becoming a general approach
for protein labelling.
In 2010, exploiting similar idea, Popp and Ball454 envisioned
the combination of two previously described techniques:
the coiled-coil based molecular recognition of complementary
peptides455,815–817 and high catalytic activity of dirhodium
complexes on carbene C–H insertion, previously reported by
Francis and collaborators452 for the selective modification of
tryptophan (see Section 1.4.2). Two complementary peptides:
one, containing a dirhodium catalytic centre (precomplexated
through two glutamate side chains), and another, containing a
side chain to be modified are thus involved in this methodology
(Fig. 96a). Because of the compelled proximity of the side chain
of interest and the active catalytic centre in the obtained
supramolecular assembly, the reaction of rhodium-catalysed
C–H insertion is largely accelerated (more than 103 times).818
As a result, the conjugation of amino acid residues with
lower reactivities becomes possible. This allowed to expand the
scope of originally tryptophan-selective dirhodium carbene
methodology first to the other aromatic residues, phenylalanine
and tyrosine,454 and then to over half of the naturally occurring
amino acid residues (Fig. 96b).818 To date, dirhodium metallo-
peptide represent the only reported method for selective modifica-
tion of Gln, Asn, and Phe side chains. The authors have also
demonstrated the possibility to apply theirmethodology on chimeric
proteins, containing fused coils,456 as well as on full-sised natural
proteins possessing coiled-coils in their structures.818
Despite its important potential, the metallopeptides metho-
dology is however not devoid of drawbacks. Because binding to
dirhodium is nonselective and thus cannot be performed in the
presence of other carboxylate-containing peptides, rhodium-
peptide complexes must be synthesised beforehand, which is
often challenging mainly due to their poor solubility.819 More-
over, the method is restricted to proteins containing coiled coil
fragments in their structures, which in case of the vast majority
of targets would mean the need for resource- and time-
consuming expression of fused proteins.
Another approach, developed by Silverman and colleagues,
exploits self-assembling of complementary DNA to bring into
proximity two reacting fragments and allowed, although only
on simple substrates, selective phosphorylation of tyrosine and
serine, otherwise not feasible.538
Beyond coiled coils and DNA-based preorganisation, the
principles of proximity-driven selectivity should be extended
to other helix-binding protein domains and to biological mole-
cular recognition generally. A significant broadening of the
applicability of this elegant approach for protein modification,
biochemistry and biomaterials engineering is anticipated in the
nearest future.
Fig. 96 (a) Modification of c-Fos (shown in red) catalysed by Max(Rh2)
(shown in blue) metallopeptide described by Popp and Ball.818 Two
possible coiled-coil alignments result in modification of GLU-14 and
GLU-21 residues, located in close vicinity to the dirhodium catalytic center.
(b) Proposed product bond connectivity.
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Conclusions
The field of bioconjugation has expanded in the last 100 years
and passed from a blind-eye modification of proteins one could
found in nature to a well-established independent domain full
of approaches allowing precise and reliable introduction of
various tags into proteins’ structure.
Many, if not most of these methods, however, often possess
drawbacks limiting their general applicability. This fact has
become of special consideration with a rise of novel exigent
applications for bioconjugation, namely the preparation of new
therapeutic conjugates, vaccines, and biomaterials. Also tremendous
progress in the sensitivity of analytical methodologies as well as
the need to work with smaller and smaller amounts of sample,
often-unstandardized patient samples, highlighted the need for
more eﬃcient, selective and reliable bioconjugation methods.
Moreover, some parameters of the mode of conjugation,
previously completely neglected, were recently revealed to be of
paramount importance. For instance, the stability of the gen-
erated linkage and the distribution of products generated upon
conjugation can be determining for the overall eﬃciency of the
conjugate.
Overall, we believe that intensive ongoing research in the
field of bioconjugation will result in more eﬃcient and selective
methodologies allowing specific conjugation of native proteins
in complex biological media, and ultimately in living organisms.
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